var title_f18_6_18528="Ultrasound ureterocele";
var content_f18_6_18528=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ureterocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tulin Ozcan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_6_18528=[""].join("\n");
var outline_f18_6_18528=null;
var title_f18_6_18529="Patient information: Newborn hypoglycemia (The Basics)";
var content_f18_6_18529=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?30/62/31714\">",
"         Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/62/8163\">",
"         Patient information: What to expect in the NICU (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Newborn hypoglycemia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/newborn-hypoglycemia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H29665073\">",
"      <span class=\"h1\">",
"       What is newborn hypoglycemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Newborn hypoglycemia is a condition that happens when a newborn baby does not have enough sugar in the blood. &ldquo;Hypoglycemia&rdquo; is the medical term for low blood sugar.",
"     </p>",
"     <p>",
"      It is normal for a baby&rsquo;s blood sugar to go down after birth. It usually comes back to normal when the baby is fed breast milk or formula. If blood sugar stays low after feeding, a baby might need treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29665088\">",
"      <span class=\"h1\">",
"       What are the symptoms of newborn hypoglycemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many babies do not have any symptoms. Some babies have symptoms that include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Shaking or trembling",
"       </li>",
"       <li>",
"        Weak or flabby muscles",
"       </li>",
"       <li>",
"        Acting irritable or cranky",
"       </li>",
"       <li>",
"        Acting sleepy",
"       </li>",
"       <li>",
"        Breathing problems, such as fast breathing or stopping breathing at times",
"       </li>",
"       <li>",
"        Skin that looks blue, feels cold, or both &nbsp;",
"       </li>",
"       <li>",
"        Trouble sucking on a breast or bottle (Some babies eat less than normal.)",
"       </li>",
"       <li>",
"        Seizures",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29665103\">",
"      <span class=\"h1\">",
"       Is there a test for newborn hypoglycemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. A blood test can measure how much sugar is in the blood. Doctors can order this test if a baby has symptoms of newborn hypoglycemia, or has a higher risk of the condition.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29665118\">",
"      <span class=\"h1\">",
"       How is newborn hypoglycemia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;All newborn babies need breast milk or formula soon after birth. This can help keep hypoglycemia from happening.",
"     </p>",
"     <p>",
"      Some babies have a higher risk of newborn hypoglycemia than other babies do. For example, if a baby is premature or the mother has diabetes, the baby has a higher risk. These babies should be fed breast milk or formula within 1 hour of birth. A doctor or nurse will do blood tests to keep track of how much sugar is in the blood.",
"     </p>",
"     <p>",
"      If a baby still has low blood sugar after feeding, doctors might give a sugar mixture through a thin tube called an &ldquo;IV.&rdquo; The tube goes into a vein. This gets sugar into the baby&rsquo;s bloodstream right away.",
"     </p>",
"     <p>",
"      Most babies only need the sugar mixture for a short time. If a baby needs it after he or she is 3 or 4 days old, the doctor might order more tests. Depending on the results, he or she might give the baby medicine or do surgery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29665132\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/62/31714?source=see_link\">",
"       Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8163?source=see_link\">",
"       Patient information: What to expect in the NICU (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?18/6/18529?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83290 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-3ADB073D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_6_18529=[""].join("\n");
var outline_f18_6_18529=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29665073\">",
"      What is newborn hypoglycemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29665088\">",
"      What are the symptoms of newborn hypoglycemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29665103\">",
"      Is there a test for newborn hypoglycemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29665118\">",
"      How is newborn hypoglycemia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29665132\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/62/31714?source=related_link\">",
"      Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8163?source=related_link\">",
"      Patient information: What to expect in the NICU (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_6_18530="IgE trends in CMA";
var content_f18_6_18530=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F73825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F73825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 605px\">",
"   <div class=\"ttl\">",
"    Trend in cow's milk specific-IgE levels over time by final cow's milk allergy status",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 585px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scatter plots of all cm-IgE levels recorded, by age, to age 18 years (n = 2498). Panel A) All values in the group with persistent CMA (n = 1651). Panel B) All values in the group with resolved CMA (n = 847). Nonparametric smoothed curves show the trend in cm-IgE levels over time. These curves approximate the mean value at any given age.",
"    <div class=\"footnotes\">",
"     CMA: cow's milk allergy; cm-IgE: cow's milk specific-IgE.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Skripak JM, Matsui EC, Mudd K, Wood RA. The natural history of IgE-mediated cow's milk allergy. J Allergy Clin Immunol 2007; 120:1172. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_6_18530=[""].join("\n");
var outline_f18_6_18530=null;
var title_f18_6_18531="Shoulder fracture dislocation";
var content_f18_6_18531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Shoulder fracture dislocation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 538px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The plain radiograph above shows a fracture-dislocation of the glenohumeral joint. The humeral head is clearly dislodged from the glenoid fossa and the dislocation is accompanied by a fracture at the surgical neck.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott Sherman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_6_18531=[""].join("\n");
var outline_f18_6_18531=null;
var title_f18_6_18532="Lactobacillus: Patient drug information";
var content_f18_6_18532=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lactobacillus: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"     see \"Lactobacillus: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/5/1108?source=see_link\">",
"     see \"Lactobacillus: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bacid&reg; [OTC];",
"     </li>",
"     <li>",
"      Culturelle&reg; [OTC];",
"     </li>",
"     <li>",
"      Dofus [OTC];",
"     </li>",
"     <li>",
"      Flora-Q&trade; [OTC];",
"     </li>",
"     <li>",
"      Floranex&trade; [OTC];",
"     </li>",
"     <li>",
"      Kala&reg; [OTC];",
"     </li>",
"     <li>",
"      Lactinex&trade; [OTC];",
"     </li>",
"     <li>",
"      Lacto-Bifidus [OTC];",
"     </li>",
"     <li>",
"      Lacto-Key [OTC];",
"     </li>",
"     <li>",
"      Lacto-Pectin [OTC];",
"     </li>",
"     <li>",
"      Lacto-TriBlend [OTC];",
"     </li>",
"     <li>",
"      Megadophilus&reg; [OTC];",
"     </li>",
"     <li>",
"      MoreDophilus&reg; [OTC];",
"     </li>",
"     <li>",
"      RisaQuad&reg;-2 [OTC];",
"     </li>",
"     <li>",
"      RisaQuad&trade; [OTC];",
"     </li>",
"     <li>",
"      Superdophilus&reg; [OTC];",
"     </li>",
"     <li>",
"      VSL #3&reg; [OTC];",
"     </li>",
"     <li>",
"      VSL #3&reg;-DS",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F186487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Bacid&reg;;",
"     </li>",
"     <li>",
"      Fermalac",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691815",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691593",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease too much gas in the stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701400",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to",
"       <i>",
"        Lactobacillus",
"       </i>",
"       or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697054",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on a lactose-free diet, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698108",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gas.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705565",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablets and capsules:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may sprinkle contents of capsule on soft food or liquid. Do not chew.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chewable tablet: Chew or crush well. Mix crushed tablet with food. Do not swallow it whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705408",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Granules:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695460",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix with cereal, food, or milk.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705506",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Powder:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix with water and drink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695335",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may also mix the powder with applesauce or yogurt.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699187",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to store closely.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11978 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-77.94.48.4-442DE206A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_6_18532=[""].join("\n");
var outline_f18_6_18532=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186486\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186487\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020905\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020904\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020909\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020910\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020912\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020907\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020908\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020913\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020914\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=related_link\">",
"      Lactobacillus: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/5/1108?source=related_link\">",
"      Lactobacillus: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_6_18533="Mass closure of abdominal incisions";
var content_f18_6_18533=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F51197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F51197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Mass closure of abdominal incisions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 567px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAI3Ac4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoqjrWr6dodibzWL23srUMFMs7hFyegye9XUZXRXRgyMMhgcgigBaKKKACiiigAooooAKKKKACiiigAoo7iigAooooA5f4m61e+HPA+pa1pqq82n+VcyI38cKSoZlHuYw4HuRXUAggEHIPeua+JttLefDfxXbW675ptJu40X1YwsAPzqT4c3kuofD3wxe3DbprjS7WZ29WaJST+ZoA6GiiigDF8Ya4vhzQm1ORY2ijuLeOQyPsVUknSNmz/sq5bHfGO9bVed/tBAn4Q69jt9nJ4zx9ojz+leiUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeZfFvwprfjXU9K0u0gtF0SCKa4uJrtt0bzMpjjUKrB9yhmcHGM457V0fwvt9asvA+mWHia38nU7JPszHzFkEiIcI4IJ6qF685zXVUUAHOT6UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAYXjx2i8D+IpIyQ66dcsCvXIibpVP4UjHwu8HAjGNGs+P+2CVpeMRu8I64PWxnH/kNqzPhP/ySzwb/ANgWy/8ARCUAdVRRRQB5z+0QwT4N+I5CAfLWGTkZ+7PGf6V6NXnP7RJx8FfFR/6dlH/kRa9GoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDO8RwNdeHtUgRC7y2ssaqBkklCMV5zovi8eHPgn4HfTLU6nrV/p1nY6bYxnBnuPJUEE/wou1izHAAHUcV6vXhvwD8M3M0WjX+rjcnhm1utIs42C/JcG6mWeXH3kby0iXB7M3rQBo6hd+PPAEFr4m8XeKLHWtG8+KLVbCLT1t47GOVlUywyrl5PLdhww+ZScgHka3je61zxL45t/Bfh/U59H0+Gy+36xqVqAZwjsUjgiY58t22u27GQACD1B7fxVo8fiDwxq2jTOUj1C0ltWcDJXehXcPcZzXC/AG3F54PHie7dpdY1sRC9keMo4a2jW22Nk5OGikYnjmRqAON+JWheK9O8P3ngc6rc6/pfiKIW+k3uoyKLi2uoyJTBPJgB1kRHKuedw2kYwa+gK85+OMED6DoN3JMq3Gm6/p17BEWA81hcJGRjuAJSePQV6NQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGf4hvm0vQNT1BFDvaW0s4UjIJVC2P0ryv4Ha0U1/WNMuoo4H161t/F9pGsjPlbqNRcLz90LMDgZyQ9d98TbgwfDTxZcREFo9Iu5FPUEiFyK5iz8Aw658O/BAF7caZ4g0TTrf7BqlrjzIJPIRWBU8OjYwyHhhx3oA73xDrNj4e0O91fV51t7CziMssjdgOw9STgAdSSAOTXl1h4it/hVq2tw+K/tdt4W1e9k1TTNSMLyJC82HltZVVcxsH3MgwQwLc5BFdBo/gDU5ry0uvHPi298TvZy+db232WKztVcEFXeKMfvGUjKlmIB5xnmvQaAPAPiGdQ8aaZd+KJLSew0OCSz03SIruIxz3Hm6hatLdlSA0aN5caoD8xALYXcBXv8AXB/G6SOD4fyXEzBYodR06RiegAvYM5ru8jOMjJ5xQAtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWZ4nv5NK8NatqMKq0tpaTXCBuhKIWGfyoA898T64sv7M17q19KxN74b+Z2OSZJoAoBPrucCvTNMtzaadaWzEEwxJGSO+AB/SvnK0iOufsbaVYJLKZb2S3sozIdzbv7SVMD2GOB6AV9LUAFFFGM0AeZftJXclh8GddvISRLby2cqEHBBW7hI/lXCfGT4n2Phn49+CbeZlNppcco1Bw/Ea3QVeRgnKKqycckNjvXp/xwgE3wg8XRhEIXTpWww4G1c/pjiuG+LPgnw23jfwX4mvdMtbhtX1ZdO1FLkNILjz7Zo4ycthdnlrtAA+YgjB6gHuVFVdKsLbStMs9OsIzFZ2kKW8MZYttRFCqMkknAA5JJq1QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRVPUdV0/TEDalf2lop4BuJljB/MigC5XmH7SGiX2s/CbWX0ie6hvrKM3IFvMY/NiAImjbH3lMRc7e5C9eldkPGPhkyeWPEWjF842i+izn0xurTtruy1KBza3FvdwH5WMbrIpyOhxx0oA+S/gzo+rS+AfA0bX90y6p4uhmt7WWYvCtnaLLNJsQ8ITIrk46kLX19XlMGi2MHxc8IaBpVtLBpvhPRJ7uMq2U3zsII1bnltqTNk8nJ9a9WoAKKKKAMbxpp39seDte0zLj7bYT237sZb542XgdzzXneoNNe/s4aJqqPE17p2l6frCyyDfte2EUzH6kRsPxIr12vM/gomn2vw3vNAuZVuLfQL+/wBKujdAbdsczkbsgAr5Toc4xzQB6ZRXNxePfB8oJi8V6A4HJK6jCf8A2arEfi/w1IwWPxDo7sTgBb2InP8A31QBuUUyGaOdN8MiSJ03IwI/Sn0AFFFFABRRRQAUUUUAFZ/iH7Z/YV+NMnht78wOLeWY4RJCPlJ4PfHY/Q9Kz/FfiL+yPs9lp9v9u1y8yLSyVsbsdZHP8Ma92/AZJApPDnhz7BZXf9sT/wBqajqB3X00q5jk4wEVDkLGoJAX8TkkmgDjdS1+60a1mjuF1+K+t7nT5ZbWSRLpnieYqfKaPJO/aylWx0GFAJzfufGV/DZ2l/5dpI0+mSXqwwz74RmeJFBbGSQJOSMDOeK7Oz0LSLKDybLSrC3h8xZfLit0Rd642tgDqMDB6jFKuiaUocLpliA+7cBbp825gzZ45ywDH1IBoAqeGdSu72XWLXUBAbnTrwWrSQKUSQGGKUEKSSOJQOp+7nvituooreGGSeSGKON53EkrKoBkbaF3Me52qoyeygdqloAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKr397a6fbPc39zBa26felmkCKPqTxQBYorgJdQtJ0Zz8RZlickqtstpu2/jEx/GsmR/D1x523xB4k1qSNQ86jVpLSO3VjhTKytEqBuwPLc4BANAHqcjpGheRlRAMlmOAK5fUviJ4P06TyrjxHpj3O7YLa3nE85PoIo9zk/QVw95pWiWkcNzc+DPD9wLgnypNY1XziwHUqJI5GOPRQTz71r6HJ4nu7iG20W10HR9GZkZ3tLWYMI8fN5bPGqFs8jKYxkc9aANr/hNbi6d10Xwl4lv9o4kltlsUz7/AGlo3/JTWBqni/XBcm3u9Y8J6DKSI/s1u0ur3jOf4RGoiw3ttf8AGsrVdH1FdXXTdVn1vxSyESXNzLaExHI+WGKAFLUED5i8m4jIAVs/LqfYIdFhtU0nwdd6WzOqyarc2sF2bVQM7ljilZgSQAMKEX7xGF2kApW72GpzzR3N7458VXkR8m5t499hFE5xhXRfIQZBzhi2ByxBIzNpuhXCTPDoXgXQtKZSVee5txK5P955CFLH1K+YD/eNb14tvp2o5M/i7Vr+B1Zjb+YIyeGwQoSA5zyMfWsi/SFWJ0fw94i0fWrhybe4lmaO3V+WLzMjyRhBgkh15+6ASQKALn/CKeNpRIZvFukxRNGwSyh0NDErYOMszksM4zwM89Ks+CNEj0qa78RXd+kcb2YtriKS3ggWBoZJDIzPGFVlBJAJHABOTu4yfE2vywWcH/CU6zplgg2s0UwvNKjmJBBVbjf83QnZtzxyMVmaTDe+ONPTwjaWN/o/hLSpXstWadhFPcCM/LZIUYnZsKB5QfnXIBO4mgDovhJA2qT+IvG00TRHxJdI9orFwfsMKeXbsVYDaXG+TjIIkWvQ6ZDFHBDHDBGkcUahERBhVUcAADoKfQAUUUUAFec+GoRH8S/iFoGoi2k0/UorTVIbYjmRJYTbz7geozAuccfN716NXnfi2JtJ+L3gnW4YoFi1GK60K8nckNgp9ogUdvvwyD/gXvwAZ+maHqt3eS2GnavcraafcG1nS4uoZJrdQfkKrLayZzFscFm53YyBzU+o+Ftes7qX7K51WzQAILy2sZRIMcgxLDCQB04l/DtTJvD2h+KPF+tpdW722pCbzrW+MMe65jREicLuBLrHKpU5wV3jGAwJ3bTw/rcFzDZy+Ib8ad5O5XhdPMSYEZUmVXdkIOVBYlcMGLgrgA5TTdIj1/z2h+GnhiBIsBZ5Ln7PIzZYEApb70YFeQcH5lNQXlxBod8ttqU3iPQpl2/Np+t/2hEgJ4Plz5b8BGSfSvSYdI1C30s2VtrMqfvty3Bt42lWM8lRxs3Zz8xUjB6HrWddy3emXLaXc3MOsvfx/wCiW+oyxQtKVz5q/LHhgFKt90nr26AHK2/i2a1tzcRePdLktGUMjeItMay3KTwRKDEpz7Ia6LT/ABTrk4Rl0TT9Wh2gtLomrRz9e+2URjH/AAI/jWXa6VN4gj/s+XQ9PEWmySRM+rp9rgjLNvEcESsFYIpVd5KlQNuOoE03w8i8hE/sjwXOIxhE/sP7Pt9MOJG2/gKANoeNLaLA1DR/EVk3o2lTTgfVoQ6gfU0RfEDwo/8ArdctLQ9MXpNsfykCmuQm0f8AsKxmvL+1vrOxtpAl0mnT3UIjjxzOhimIdB/d8vdxyABmptUS60a7ZpPEd7p1jz5Ml9rlv5k4A6xxywupU5xlnB7kCgDtYfGHhmZd0PiLRpFIzlL6IjH/AH1VbVfFlt9kZPDT22t6qxCRW1tcK4Uno8pBOyMd2P0GSQKx9N8PQ+ILSK9i8V312GUbisOmz7WxkqWW3IJHsa2NC8IW+kX096t9cXN9Lb/ZhcSW9rG6JuLYBihTPJzhsjPbrQBN4U8O/wBkfaL3ULj7drl5g3d6y43Y6RoP4Y17L+JySTXQVzX/AAjmqf8AQ6eIP+/Nh/8AI1P8I3N49zr9jfXkt7/Z1+ttFPMiLIyG2gl+bYqrndK3QDjFAHRUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSOCUIGM9sjIB7UtFAHGaleaLYyyrrfiC6vLyNSz28M7Ky45x5UOD9N2T7mqHh3QrjxXa2mv+I7wo8sjXNra6VcMkMcZUrGWkADySbCQXyBz8oA5Pc6fY2unWq21hbxW8CkkJGoUZPU+5Pc964xpLbR5b3SPCNraaV5MrSXpWzaWY7wpEsUC4MgJkIL8hShGGwcAGneeHPCOmub7VrPTTKR5f2vVHEz4/u+ZMSce2arXOqLFZTP4R1nwtHp1jCZJoCm5YlGWZi0cgCD/gHr1qZItH0S5GNO1LUdTDBWu3spbiVyQOTMV2gewIUdAB0qtrVzd32n3k914J+1TJHILfz7iHJQjBDsu54yRu4RXOMdyQABNM1nxrq9pHcQeHtK02FuVN/fSmSVezCMRAoCMHDkOOQyAitP/hJRpUAHi77BpNwzbYit4JI58DJKFgrDHfcoA9SOay4PEuqeX58qWEji3CpaWsvmgy4yZpphlYYhg4ySSO5bCVyuu+MrG41q1v8ARfEek3M8ybbU2is06QvgkTKziLb/ABK8hj6ADceGAPRbbxRp9xYfa41uvKjcJcKYGD2xK5y64zjp8wBHOc7cmvMdQ8Wf8Jn4QuI/Ed5p3h+0v545bWAatHDMtupBC3DBi+52XPlxBSFITeDuIn8Xa/IuveF31G3uo/DumI135lxqdjC15ejCQh8yjKKC7krwWK8YXFVdT1G6utXuLrV/KtnSGGW1tNPgj1OV4S5zKjtAzyO+QgVPkTaSWNAHUvPpF1oGjW+lQ6fNFo6q4+0FG+yRpGyI7FixjUjkkncE3A8nFafw0ElzZ6zrDJItvq+oG6tfNzveBIYreOQ5APzrAJBkdHFcUkts1slrq0F7rniubM2naLfsojiBJ2O9tGFSOKPIBmkQMSrFeSin1jQbKXTdD06xuLp7ye1to4JLh87pmVQC5yTySM9T1oAvUUVn67rWmeH9Oe/1zULXT7NDgzXMojXPYAnqTjgDk0AaFFecnx7rXiFQvw/8LXV5byfc1bWM2Nnhk3LIisPOlXPHyoPr3py+CvFGtfvPFvjjUI1LrILLw+gsIoyByvm/NM6/8CH0oA7fVtX03Rrb7Tq+oWdhb5x5t1MsSfmxAryv4u+KvCOq+HNO1Cy8QaTfyaDrGn6qy2d9HM0SLcxxs7IhJKgSkfUiun0z4SeA9PlnlHhmwvJp23SS6iGvXY+u6YuR+Fcf+0X4a0PRvgh4ol0bRtM0+UpbIXtbWOJiv2qE7cqBxwOPYUAbMtx4b8ReIdY8FTa5HFrFvcNfWE1hchLu2L5MgR8fLIrebuXn924BBBIqoPE2geIvEo8L6lqfhrU9R0+WSCRbuymS4Xy1Jl8vfwGwhO9WI4zXaeOPD8utW8DW1ppl28TZeG8DRswyMNHOnzwyKRkMAfw4Ip3Wtaxa6P8AY08HeIbubymiUxX1rzxjPnGcOP8Aexu79aAM7wvFYeJdQvTY+L5dc0WFIzbLY6sQ9tuBzHMYiHY8ZDu24gkEZUs2zd+FtGnvbfT7y4nu4nRpv7O1CU3cciphd483cylS6/MrDGRXmGjJY33gnT9K16ay03w7FIq3drJaYuUKMGSCWRJQ8Uq/KdxUs3DZBYitrTPENhrxOkXOnTTWGk3JjtdV/tJnumTy0MVxE5w7Mdzq+CcYwdwLAAHqa2q6XpIttDsbVFhXENqp8iIc9Mqp29zwKytN8Q3Wo3E9rBpqx3cCOJBJcqUWQHC/MoO5CQwJHzKVwVFcZ4k1e2srSKDWPFUz2c8gEQ1DQpZGLdvmiCA/iMeuaZYavpOjaDPdaXqiwajPHg3eopHDbWcSliqNsHlQBjnauGclwzK20gAHZJpHiK8O7U/EQt1Yc2+nWUYQexaYSFvrhc+gpvhPwq3h6+upTPbXzXGS95LbBbxznhXkU7WQDhVCoFAUAYqpoHiWa1tSfEMWso0gWSN5dOLIEI/vwhlH/Awjf7Iql4h8d6JOwj0TxSkWqWrEtaQ232kyH+5LHwy57HcnPU4zQB2Wr6gNPS12xiSa5uY7eNN23JY/Mf8AgKB2x/s1fryWy069vPFOmatb31vrGqefl3tlmS0somU+YzM0soZsAKIo3QEkFgQMj0TRJL8Wd5c6vE8LPPJJFbgiV4ohwoO3OWOC2BnG7aCcZoA1q4XS59bi8R+Lxo2n6bdxnVU3td3725U/YbTgBYZMj3yK1f8AhNNL/wCfXxB/4IL/AP8AjNN8FM1xfeJ74QXUNveakk0H2m3kgZ0FnbITscBgNyMOR2oAd9s8Y/8AQC8P/wDg6m/+RKl8a317p/w/16/hZbbULfTJ51aNt4jlWJmBBIGQCOCQM+naugqK6t4bu2lt7qKOa3mQxyRSKGV1IwVIPBBHGDQBxtxqOq6VbQW8P2ptUupHMVveBLlmjRQWIKPGqjLDJZvwOaPBHiHU/EOqtcSNBHps2l2N8ltty8TTI7EBuM8jv6DGOa6zUdNsdTSNNRsra7WNt6LPEsgRumRkcHk80230nTrea3mt9PtIpbeEW8LpCqtFEOiKQOFHoOKALtFFB4HNABRSKwdQykFSMgg5BFLQAUUUisGztIODjg96AFooooAKKKKACiiigAopkU0c2/ypEfYxRtrA7WHUH0NPoAKKRiFUliABySe1JFIk0SSwuskbqGV1OQwPQg9xQA6iiigAooooAKKKKACiiigArP120kvLHZBFayzI6yItzuC5Bz1XlT74P0rQpHG5SuSMjGQcGgDzjVtU1c310kmm38DEhJBBNeyQsRxuUx2xOCP7rLn2PNZ/2JJjZya/pWq6vbafl7W0jsY7Kzt2ClfN/fyB2fBYbnc9chQeaseMl/s27WBpbw6YlvJcTTyX9zM5ih+adwokCgqNkag5LPNnGIyGz3awsr+NdS0nQ7R7YCW/P2NZ3gxiVowxBLssbW8WR99rkMoGNtAGJf3AcMsGpaekYJT7HqWtrNIATwvlRLMDjOMc9KS3S7nQQJqEVzc2y+WLKPw5d3KQIeDtiLQwKT8w3GLOGPrW9p9z4kbTorbWTcafdXlzdP8A2fE0vmBRM20B4lyIY4jAB5W0uxJLgZJr6pl9Hn08SMkFwrW7RWxWFGZsqyKsO7kg/dd55OpETUAYk/h8vCjatY66IGl2xqmlaPaQtIegWK5Zjk44GM8cVuW+qa5JcSRrq/jbeskkZHnaIctHjzMZjxhCwViDgMdp+biqtkLLVfEWiOdTtp5/t989tG0UiLqV4AfOnRlY7IYVXykcgnK9T8pa3pFrYW95Y6lHHAulixh1JIjMxjtLSPaYc4XMmWLvHHhfmV3cs4QKAc9otr4q0CTxTq2oT+I4bmS/e6leyttIuG+yqgjjMqKdwk2RncEG3I4Gd2a7aBFpEGo3N5dwxvcXBuZ7nXtFurMOWAX5rq2lEKJ90cJjnpk1o/DfRtK0XwpcWmjXS3sN5psFhc6hNdNZGUTJJcxuIzG4VglySTuJHJI61cuNYvdVt7c34hWNEuVdYo3VVsHhXzYQudx2obc+pmkRPlCsAAdH4Pu7vQdPLaX4L0aXTpDmW48L6hHOZHA+8yyJEWPbO5mrqNL8caBqF9HYNemx1STAWw1GNrW4YnsqSAF/quR71wPiq6k0LSBr2nW4h8SWDG4nFsqZu4Ez5ltM2PnG2OYCQ87oWdQAdp7f4kRz3OgyWVrpkOo3NzHKtvHcQJPD54jPliRW/hJ6twAAcnkUAZFz4s1jxZe3Gm/DyOFLOEvFc+IryMvbRsCFK2yAjz3B3c5EYK8ls4rR0L4eaPp+ppq+ptc69rynK6lqriaSL5i2IlwEhAJOBGq/jXm3hpSp0yLT7y50RRCpv7Pw8Li7gtpiMyokSebDH85bpjHUgnNex+Dp7q68J6PNqC3QvWtI/P8AtUXlSl9oDF1wNpJycY70AbFFFFABXlX7St1Zf8K0/sm/uo7RdZ1GzsVnkBKxfv1kZ2HoFjYnpXRePtC1TVL2yudMtoLtYLeaMwzanPZqrsYyrgRKfM+6wwxXrwRk15LoWo3a+Nrc2NvYWE2nTz2959m09Xu7mYxj9wZmuHWUorM5SOZnG1Mx5BCgHrV74m1u+hlbw9on2W0RWY6prr/ZYFUdXEQzK2Bk4cRAgferhtTuzf2j3mpT6/4ptjwJVl/sfSAeSMYYPIhx98+cgyMsBkjV8SrpP9h6FFo0cc+g3N5M84nM0jzXiqfLW4BV5HIdWLLICwaJFI4xVfT4dTu5mmttZl1Py288OLlboKTyCoUkr1xxAeMjGKAMr7PEjRtBp2j2UbyfZ0bTdJt1dnONsYluCQZckDZKsTEngHjLNT0GVb6PVtL1xLvS7ix+z/Z7rT7XzkuopsnMHkAoFRpBIVUupCkqwQAaUNhFbTXEzW00UNqBHcx2zL9kuFbKmC4XY5C/NyqqNoz+6jyC2bHayXl3pk+tXlrbXUF67aRJbRyNPfrNYyoYnkAlUkRomJ0Mm4IAQr8UAN/0iztWBsfDbvJteJ20hITJGxAU745VAY5wrqTE7bV3qWC1dnxaNHanUrBmlTzooILnU7fClQQzKHcRjDc7hjqOxqPQLe1tjFDoctvb2sYdWaCSKWPLAnZti2o5cgAxSxRswJKyBl5nv7CaWSeZdC1aVRcNgpb7ZWYtncHOASFI5mi9cSkgGgDMt7AxCKWAXVi7orM0XiK5RRGTjfv8p0kiUsoJVmCbgTtGSNm8u/EWm7YZbPUJ7OLpdWslreWydzkm2R/XJOADyTVrw5c2ME99AdXjmnntnM+nzQOkZZiV8yV3VwvBAJYMckqzyqE214PD4WfdHNoEcpUEXCCNSg/vJLDFCxIHPyup4OOhFAGk2v8AjYaf9qtLYzwSRGWGVtMinVxtypDQXpJU+oQ9enauittM1+50q3u9d8Tz6ZeiHddR6XFALVSMksv2iF5AMYzub8BXP6Lf3EnjPR7O4nvLOG3aeGKzjuUjSZlRyzyoUzMw9Y5XAOGZUORXptAHmv8Abeh/9Ff/APJvSv8A4xW3pmmzarai50z4gaveWxOBLbjT5EJ+q25FdfXNeE/+Q940/wCwtH/6QWlAB/wjmqf9Dp4g/wC/Nh/8jUf8I5qn/Q6eIP8AvzYf/I1dLUN5cwWVpPdXcqQ20EbSyyOcKiKMliewABNAGB/wjmqf9Dp4g/782H/yNR/wjmqf9Dp4g/782H/yNWumr6e9xZwJe27TXsRntkEgJmjABLKO4ww596vUAc2nh3UwwJ8Za+wBzgw2OD7f8e1SePFvpvDN1Z6VE8l5fFbRCpKiNZCFdywB2hULHdg8gdTxXQVX0+9t9RsYLyykEttMoeNwCAwPQ80AefaNYavAmmaBPb3dlY22ozxObKSTyzamF5YlWUKp2qzLHkbTlMfXMWHxEqRagseq/wBuTeHooom8p9rToZS4kGNofawID4BYjFeuUUAeZ2MOtXJ021i1LWFs5tTxNIttPFJDD9knJUvcAsVMix/MehYAEHGIbr+2YFvElTWYod+oNaGxhfc1x5/7kvsXlSvILfIcsWzxXqVFAHLeHYNVl8Q6rc6tc3ipEYUhtxxbnMEZdl4y3zlh1IGOxzWLrsXiIv4ourK51ICK/ghtoFU7PspitjM8agBnOTMMqSQQwXDV6HRQB5natqKtZx6pda7No2bkh7S1u45lkzH5aPkGZlAMuGbgnhs4GU0YX2iXAcR635Q164lvkNvNKGt5EuTGyhVO4F2iLbM4ON2MV6bRQB5b9p8QeVoNzOurzzFQHsxHPCQxnPzs6KUyExlJcLgZBGSa2/iLJqcE9jNpo1C4EaSH7FarOnnPldp86JSFIwQFk+Q7snG3NdvRQB5xb2WsWOsNdael8JbnWrtHjff5BhNrKyMV+6AZUj+frzjPOKzLCfX49LP2t9YnedYEu4za3iNbSZO+QMvzOM/KUgIXoRgZJ9aooA8p0W11Sa+0u71hdXeUWmpWaSCCZQ226xCJF5KhogCC55wMknmt34dWeoaabS1uPt/2Q6LZOy3JciO4+cOq7vukAJlBjGBxzz3NFABRRRQAUUUUAFFFFABRRRQAVW1MStpt0Le6WzmMTBLh1DCE44cg8HHXB44qzSMoZSrAFSMEEZBFAHjmja9b6JpMzy2ktxp0toClqirKVzFJcKjCRlGUt40kfn55JzzyAIfsHmyS6nq5troyL8sCgXECsXZ1YDCxGQu28cO5JGEJAxoeP9LbSIdYkaWK4m1aKW2i+0TCLEcm1rovKQArMiQwxLg4McfYuQ3UHudZ1CSW0sNTuYZTDtW1gKxMm9o5lEkgTCtD5ciqGxvBBzyCAYmh6vcapppvbTQbWCwlf+zbMQlZRfXS7vMeCHIVW3I6hsqiqsjszKoAq2sFwLMG/wBZ1HUTJP8AZYZ4J4baG8mX/WRhvJLvbRqsjSyMVRvLOI2GFHQeLWitJUj2LoCR6eul2i3mp2tr9lgaRfOMbCRmDuiRoGxldgI5JrD1a7N1KY7IaHfQCH7NFa2Qu7yFLdSuy2WOC2P7gBd0iggzMqKzLGojoAux3WjTeFdH+zWk0OoG1vLGOayt/JMUMkvlxzLExDIZmePyY9w2i4JGFUsC7vdNsLS/1i/h88RWzTxxLlYLmNba4zHFt+4yRQTKhy8W0Eqd0rNVezllh1uy1ODStTW7jmimuZp9P1OY3RRbkFmH2KMbibpz2VdqBVCqAI7d7yyg0/y5tbzZwCKFU8G3shUrb+QjKXOAVQykBhgmVsgjAoAsM2jQ+EdCt9K07VRptzowu44WukVh51vFbRyyzFmaMrC7qoCYOyRgMR1fstQ0P/hJmsZnkcQhJrqGb5p97TG7ASCNfM8wzSKGXBBETggFefN9Pmu76zubfVPDPie2htCLKCTV4byG1S2ji8qDMNpDvZjHJJviZ1jy7ENhyF7bw9D8P288a/4utFW5dnm08wf2HbTE45kjbbLP7+bJIDkkjmgC/e6lFrmsPb6Zo9xezQOBJpdvKJXOMFUu5i3kWyZhQGLLyMufl+Z1Pap4Uvtek8/xzepdw7tyaNZkrYoMggSZw1wRjnfhD/zzB5rovD40ldIt08PfYRpaDbCtjs8lRnouz5Rz6Vo0AeV21p4o+GMf2bSbGbxR4Ji3NDaQtnUtPTBPlpuOLiNcEKuRIN4HIWt3Sfir4J1F5Ij4gs7C7icRy2upsbKZHwPlKS7STzjjI967es/WNF0vW7dYNa02y1GBTkR3cCTKD9GBFAEsOp2E8ZkgvbWSMDO5JVIx65Brlta+KPgvSZY4JvEFldXkknkx2lgxu52k7L5cQZgT05AFSv8ADLwK8iOfB3h8FTkbdPiA/EBcH8a3NE0DRtBjePQ9J0/TUkOXWztkhDfUKBmgDhZNR8beOkFvpWmXPg3QZgvm6hqBX+0nQ/eWGBSRC3BXdIcgMGVciuq0/wAFaBZeET4ZTT0k0hgfMimJdpGLbjIzHkvu+bdnIIBGMDHR0UAcBq2kaxpWmz2UsEvi7w7KNr2k0irqECjGNkpKibGMgsVkBGd7tgVxUUUd1ALLTLy+1W2s5VklWItDqVqP4UuLSVCQhON0kUYcjpGxJevcndUUs7BVHUk4Fcn4sl8E6i0cfiS80U3Fud0TzXKRzwN6xuGDoeOqkGgDzvSdT0+4mks7PUDe28kbvJo7TwASkN99xJI06kOPviMNx0yBjWuzoUN5YG2N/DrunQz60LOSGVmudqPbCVwQrYDTkB2Cu4TcxIG6k1nRdN1BontL+/1OJRiFNV0OXUUjBOQY7jakq467jMa800TxNp738mv2NjfCK7zYW94njCK2Y2sLuqvHBcyB0Dtvby3JxsyOpJAO8uNQsbvTxNPdw3duFOEl1HzWVeCdyy+XMAcfwSPyOjVcuoRAb2LTlt4NJiijjvDLaxeXNtXcTcqiMyEbjndGowCTgZrl4fEWgzata3Y1a7OpxRidZJtW0aURE/LxIwYFh0yDuxz353muJ/EE0cq282tyR4K/aotKvduDnjyJ4nI746HuDQBjT63d6aLFdNtLnVZLoOwXT7iWHKqAQylbiOJ93O1IgRgDnkCrmny6fdajPBe6Z9hgi09LnVr2e5FnLBEx/dLLC4eV5NhlG5ieJHUtlsC5dyaxa+e0NsyRspaQXdnex737F2CSIw658ySQDjAAGKq2bWGpzWhfUDHe2bxzQizt7O4ijdXV8NCjl8ZRCSqRt8o+btQB6P4I1HSJrvUrXTrO5s78tFPfrOpy1w1vCWBJ6uqNCGOByR1Oa66vH/D2m2umXVvNeTeJoUtpzcLHZ2WoYlfcxbeQn71JNwZhIDJvXDSSrtx65uaW23wHYzplDJGeCRxlTg/hwfpQBJXC6XoNpq/iPxe91NqUbR6qigWmo3FqD/oNp1ETqCfc5rV+x+Mf+g74f/8ABLN/8l1c8N6Rc6Y2qT393DdXeoXQupWhgMKKRDFEAql3OMRA8seSaAKf/CF6X/z9eIP/AAf3/wD8eqbxnpk974C13StOR5rmfTJ7WBHlyzs0TKoLueSSRyx9ya36KAPN9V8DXkV68mlzPN5kF5DCzEILRHibyol5yQHd8EDIBA/hFR3+kazqq3sl3peoxRMlkI7YyW0u9oxLv3xmTYyZZcgsCeD1GK9MooA8+0PR9Ri1Gxm13QluWW3tVt2t5U8vT2UtvAVnyvVT8m/I+XJCjOJp/hHXIRpQvoL0+RaWqQm0e3LWkiElwS7ArnjLJu3DII4APrlFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHE6tZXGna3IdJtroPckzPJp9hEZTk8hp532dc4GOB0FVV8N6tqKr9ut0ZWOWOq6jLdZ9mto9kP5HH869AooA46x8FvaM7W2oQaczdTpWmW9uc+uXVzVo+CrCZCL6/168Y/eMmr3KBvqkbqn/jtdPRQByS/DnwqHL/2XukIwXa4lZiPcls0v/Cu/C4GF0wpgYBS5mUr9CH4/CusooA8X8daNH4W8XeHJW1PXbXwlqZbTLgw61dqbO6choJcmRvkO1kxhVXduJORjtk8GX9vA0Vp408RiMqQI7n7Lcqf94yQlyPbdXQ+IdF0/xFol5pGs2sd3p93GY5onHBHYj0IOCCOQQCMEVwOgeI9R8CX9v4b+IN409hK/laR4jmPy3I6iC5bok4A4Y8SAHncDuAI7j4c31pcC8s4tBvLvndLBDLo9y/1uLZjkcDgx/j2rY8Jah4gi1u30q/ttSkt/Id7iTUIk3W5G0LtuIh5cwYkgDAcBSW54Pd0UAFFFFABRRSBlLlAw3AAkZ5APT+R/KgBaKKKAPKtN+HV7Y2MFgNG8E3K2yiJL68sGmmlC8CSReMyEYLfNy2Tnmtqx8DX6JJHceITZWrkZttBsItPQjOcFv3kg+qupruycDJ6V5jqfjPUvGd5No3wumt3hjPl33iV18y1tCcfJCOk8u07uDsXK5PPABz3jPwnoWueJ4fB3h6xFxqLNFda3q1y7X02nWwO5FEk5fbPJjCg5ITc23GDXsFro2l2gcWum2UAcgt5cCrux0zgc4qp4Q8M6d4T0ZdO0tZSpdpp7id/Mnupm5eaVzy8jHkk+wGAABtUAYPijwrp3iDTFtZ4xBLE3mW1zCoElvIOjLxj6g8EZByK5jQtP0O/vpNB8XeG9DGvRJvDGxjMV9EOPOiyPpuXqp9iCfRax/FHh+28QWKRTPJb3UD+da3cJxLbSjo6H9CDwRkHINAFBfA2iW+46VHd6Szf9A67kgX/v2rbD+Kmob7wvqcsflnW49Shx/qdZ06G4T8PLEZ/PNSeGPEFy98+g+I0jt9fgTerIMRXsQ486LP4bk6qfUEE9TQB5wPBMkZG3wv4XBXkNZXc1gD9VjjPftk16LGWKKZAFfHzBTkA+x4zTqKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACigjIIPQ0CgAooooAKKKKACiiigAqnrOl2OtaZcadq9pBeWNwu2WCZAyOM5GQfQgEHsQDVyigDzNNB8V+A2L+E7iTxH4cUgDQr6bFzbJnGLa4Y/MqgjEcnZMBsmtrwv8AErwx4iuhYxXxsNZBVX0rU0Nrdo5GdnlvgsQOu3cPeuyrG8TeF9C8UWgtvEOk2WoxKGCfaIgzR5GCUbqp9wQaANmuIuPh3bxXn2nQfEHiTQ23O5htL8y25ZiST5M4kQDJ6KFFZp+Fr6UM+CfF3iHw+EjEcVq1x9utIwPSGfd+jCmtpvxa063MVj4h8Jay4A2zalp01s7HvkQuVH4D8qAJH8J/EKOSX7N8TFeNh8outAgdl/FGQfpXjPxl+H3xUu/EXh+7sNUfXdXCzrFe6baJp72yLsIWSYMAASxKgt1346mvYzJ8Yfs+0W3gDz8ff+0Xm3P+7sz+tMhsfi9qETQ6jrXg3SAc/v8ATbKe5kXjsJXC/nQBS+D/AIA8YaGsV9488Zanql0nzRWCXTvDGSpBMjt80pwRxwoIz8xwR0GtfEzR4L2TS/DaTeJ9eUYFhpOJRGclf303+rhUMMEs2RnODWWnwoOryRS/EDxVrXigrjdZuy2lg5U5VjbxYBIPcsc9wa9B0jStO0WyWz0ewtLC0UlhBawrEgJ6naoA5oA4MeCtb8YOZ/iRqK/2ax3J4d0uRktgMsQLiXh52HyHHypuXoQa9CsLO106zhtNPtobW0hXZHDBGERF9FUcAfSp6KACiiigAooooAx/FHh+28QWKRTPJb3UD+da3cJxLbSjo6H9CDwRkHINZ3hjxBcvfPoPiNI7fX4E3qyDEV7EOPOiz+G5Oqn1BBPU1FLbQTTwTSwRPNAS0TsgLRkjBKntkEjjsaAFE0RmMQkQygZKbhuH4VJXnL+GtQvvFHiK/hjt7cw6pFd20slufOmZLK3UKsmQBGWDK2Ac4de5xm6d/wAJK+kFft2sLeTSWCXCGzmDwsbqMTuryApjYXyEzGAucAdQD1cMpJAIJHUA9KWvMNU0q7j8Q27zrq0ljZazE/2iFHaVozpzx78oNz/vGVSQDjJzgZqK+n8SJpusPZf2ydXWw1Ezq0UhiEoz9m+z5G0nptEecjO7LYoA9UorzTXYtfs727tLKTVH0kXsLSzHzppPLaBt20ofM2+aEyIz8uegXNRSX/iKzsbiIyateSzWFqtnNHYTLmRbibzSwK5RvLMOS+CwGeuaAPUKK8+az1i51uBpp9YWCfWp7WZUkkRFsxbyupGMbQZFjAkGDzgNziun8GNet4YsP7U8/wC2KhRzOCJDhiAWzzkgDnv1oA2qKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoooxznvQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVl6Drtlrg1D7CzlrC8lsZ1ddpWWMjI+hBVge4YVqVwXw9kb/hNviPFEF+xLq0DoRnPmmzg8z9Qv60Ad7Ve6vba1ns4biVY5byUwQKf+WjhGkKj32o5/4CasVwnxdJs9L0DWTcC3j0nXbK4lcsQBFJJ9nfp22ztn2zQB3dFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHk3xr1vX9P8AEXhLTfDt7cWx1BL8yJBJDEZGjiRky8oKgAkk+oyOuK6/4Wa5L4k+Huh6rdXDXFzcQfvpTEIy0isVb5RwOVPTg9e9bGs6Bo+ueT/bWk6fqPk58r7XbJNszjO3cDjOBnHoKvW0ENrBHBbRRwwRqFSONQqqB0AA4AoAkooooAKKKKACiiigAooooAKKKKACiiigAooooAK4T4ZkS658QZz/AKw+IGiJ9ktLYAfzrt45VkeVVzmJtjZBHOAePXgivF/BGka34h0rxza6drsmkC58aXwuru3X/SBbIFjMcR6I52KA/O0c4JoA9rZgqlmICgZJJwAK5v4j6UfEPw98RabAgmlu9PmSADnMhQ7CMf7W015p4n8NIviDQfh7Nruq32gahNJqupLf3xaRLaPy44rYSEbmSSd1BGc8YGOp0xo8Xwk8V6dc6J58XgjWp1sbyxMjyR6fdOT5Vwmc7EdjsblQCyHngAA9G8H6sde8JaJq7Kqtf2UN0VXoC6BiP1rXrg/gosNp4JfSbeUyro+pX+mgnqFiupAgP/ANld5QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFZnifVV0Lw1q2ryLvSwtJror6iNC2P0oAxfC/iW1k8LTa5qt/BHZyajcxJO5CoE+1vDCCfUgIOe5rmvgQWVviJFIux08Yag20jB2t5bA49CDwa5mC0iPgn4KeFYpntptRubbU7iFwT5yQQG6mVwfWUpwe59q6bxBovifwl48vfFPgrTY9b0/WVjTVtINwlvIssa4W4idvl+7wy8EnHXOVAOO+McE2r+KPHOoaROVvvC3h6ykVhgGGYXRvCR3zst05zxk+tet+PNGt/G3w51fTLfybmPU7Bjasx+QuV3RPn2YI34VleBPCdwdL8RXvjG0tzqviiZpr+1VhIIbcxiOO1MgAD7IxgsAASzYz1POaV4N+IkGi2HhGfXNKh8N2ciRDVbJ5odRezjIKRAKAqPhQhcN905+Y5yAO+HniXStF8FeFNXgZpF8Z6xm8d5PlhvZ45GkCDHTzotgXtuJzXr1fH3xxiurPwl4l8J20VxK2leK11O1WGIhYrS4tbm4wgA4VCs5JHAwT2NfQfwS1/xD4i8AaZe+KrSJLt4I3jvIJkdLyNlyHKg5STsykYzyOpVQDvqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKR3WNC8jBVHJJOAKw7jxj4Zt5PLn8Q6PHIf4GvYw35ZzQBu182/tk+JNa0K08PWmj6hPbW2q299aXsKHKzxnyOCD35IyOcMwzgkH21fHXhxwDDqInBG4eRDJLx6/KprIvtK8MeOtd0TxNLdtMPCs9wBFInlpHOyxkmVZFDKUAVh0wcHtQBynwvj1XVPiEn/CQyRfbfC2g29pLbLbCNILq7PnMseGI/dxRxREgnPJ4zivZ688+Bsclz4SvPENwk8U3iTUrjVxFPgtHE7bYVyOo8pIyPrXodABRRRQB5b8QAvh74seDfEbqDY6ur+Gb/dlwfMJktgE/66BwW9GpvwLgm8Lx694BvtyvoV202nlkx51hOzPG4bjeQ/mqxAwCMdq6X4t+HJPFXw61zS7YP9ueAzWhjbawuIyJIsN2y6qM+hNcvpniLSdYsvBHxBVp01S7sZLWeLTtMku2uUK5lg+RS6iOZAwY8Da453k0Aer0VyCeP9OYEnSfFK+x8P3nP/kKnTfEHQLdd15/a9pGBkyXWi3sKD/gTxBf1oA62iuf0/xr4X1AgWXiLSZXP8Au49/4rnI/Kt8EMAQQQeQRQAtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFU9V1Sx0mBZtSu4bWJ22K0rBdzYJwPU4B4q5WZ4g+3LYSS6fOYjGrOyx23nSyYHCoCwAY++Rz2oAzZPHfhiNiH1m1B6dT/AIVXk+I3hJOut27E/wAKK7sfwAJqC60zxLPaWckGpX8d3N/rkmngEdsOvPlw5dugwCB1+bgZp3fhXxeLZxa+LfNnYrtaWFoxGNw3fdY7jtzjPfFAGi/xA0tot1jp/iK+YttVYNEuwGP++8apj3LYqGTxL4qu3VdK8EzW8ZUlp9Z1KC3Rf+AwmZj+IFcy2m3VxqM9lL4m8RTwJMLWa9tIrhBFJ3UMspAPIyxjZBnk+mjqnw50azeymisL/X715BCy6tdm8icbSS0rTiTy1wDzGoJO0d6AKF34r1Z42i1Tx34P0m4Zv+PXSLdr+6CjrsLScn/ticVAZtPvNWhtbnVPiNrt7Mu9LZY5dNAUAjc3lpbqq5BALkAnoTXVQeEdVtrlJbLVrCygiKmGwt7B4raIjvtjmTeeB98kccKK05bW4sLebXL+6srfUoLVkuZPMaKzkjRiwaTdkptG75snbubO4UAcjbeCgEaSH4feFi7ch9VvmuJz6biYJOf+Bmkt08S2N59mktrHw4Jrz7LYw2DW4tpYxEHBMjRF9xIkAXy1+7+J6FvGGlappcyxXl3bSDGZrCP7XsIIIIaNZEI9j2PIFZ1nb3Piq6jg1O+nn0+1xcxTNpD2EglAIVo5HfduXOSyIBg4JwSpAK/iWz8Q6boWp3+oa9PaiG3dopob1MiXGEXY0AQ7mIXBI68c1R+I1idL8MHwboVzdS614zvZYPNupftDRQuAbmX5yMpHCNoAOeUA5qvZa+fHGk6lBpEWoa7aW8Lz2mo6tafYbSWQoyogOF8xgxzkx7Vxng7a3vhR4dkWzi8Xa9eHUvEur2cXmXBQolrAQGW2iQ8qgPJzyzZLc9ADudMsbbTNOtLCwiENnaxJBDEpOERQFVRn0AAqzRRQAUUUUAFeL6dpVroPxQvfCesSXsWk63cS65oMttdzQMs5Qi7t98bKQPm8xUHy4PJLYr2iuQ+Kvh218ReDrkXF4dPudOYalZ6gOfsc8ILJLjByByCMdCcc4NAHnw0ixvpdXgbxV48/tSLUJY5UsLq8nitUVjsiUxEoMp5bfMxfJO7Byo3dD8E6pFALvTPFPiG5LsRjVLm7ikj9wshKnB7GMhugI61leHfFGvJ4Ngn1q1h8LC3tpLhrPT2iuJ7oKQZbkO5aOGHc5J3hm6/N03d7o3maxokF1ofi974bywuV+y3MTnABjYxooKgg/dKnOeemADjJ21yDRLqbxNqum3Zs7z7NJHr9nFFDIMbiIiEXzDgrsYY3fMCoKms3ZbLfSvpXhzRhEqvKBo2pXljMcNhVVYYgJCQVOeAOc7cZr0nw/FqV7q0moa7p2nQ3FuHtYpIpJJGADfeXcoChxycc8KpLbeKup+PLTSXtptX07UtO0uSTypL67g2RQk/cZyCdqk/LlsfMyjvQBwuk6/PDILW8uPiL4cuyMLDe2SajCzdSEk8uRpO/RgfYCt/T/G121wkFt4i8JaxIeBbzyPplyT6bWMmT7bV/Cuyt/EunzugjXUArkAO+nXCJz33lAuPfNT+INGj1uzFtPcTwxbssIwjB+OjK6srD2IoAyovE99BxrPhnV7MA4MtuqXkZ+giYyfmgqeDxt4alkETa3YQXBOPs91KLeYH0McmGH5VwGreEtN8Pa9G2qJpsmmXqFTf30EaixKIdux3ykbYwQqqqHB+UEEmIC4uL2x0vRPHceo2NzcBXtjDBcTbdpyR5uRsGN2VGBgAL82QAexQyxzRh4ZEkQ9GQgg/jT68uufhxapBNdz3Hhaa3CFpJrvw5buNozksysvA5rX8JeALfw/rMeowweHI2VWUHT9CitJMEYx5isTj+dAHdUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZOpQa3JcMdO1HT7e3I6T2TyupxzyJVB/Lj3qTW7W4mgE1jNNHdQAsio4AlGQShzxzjG7qOvrmKz8Q6XeTJam6jgvX4+x3JEU2cdNjcn6jIPYkUAcTp1vqeoyLd6Ne6/PHIyu2pmKxtFvcKQrH90XdBn5SUAIwQWHNIiwrfR3Guf2tqz3DLDDdw6oh8lGkWPKRxeTtG8gF1QtnHJAGPRdOs4tPs47W3L+THkIHYsVGchQT2HQegArkvEGsQXYlivfCmsXEipJAG3W0R2uNrbXeZcBuBnPXHfFAGk2g6tGoWz8VaiqcYFxBBMVHoG2An6sWPvWF4v8IXU+i3FzLfX2vX8TJJFDeFBHGA2WMcUaBC4GSC6SE428hiCywttV0PTZ9SvPEOk6C13M9zNYXQW4srTcekbbomyfvMd20uzEAZrY0vX0g8Mx6i2s23iB7uQtDLahIom4zsQAthQBklmYjkkgdADnr7xlpn9q+FrZ7Oz1DxHLLI0hjmw9nDGhE0zFU3AlTgRFQWLY4wcXbSTw/ba/rPiXTPP1nW7iECSaSQH7Jboq/ukyB5cYJ3sqgsWfJB4AxLDWb+51rXJ/Ffhy+1C2vLhTpViGsriC3tEj4mL+ZtQyNvJLNjhVBNZn2m1hm1HxHrmn6PpzLbJb6forXMltPC6yElCqriSWQnqi8FFQFslqAOk8QtfC70qfWrq3urT/j7t7dXWNbq8IxDDGud7Kp2EZHJLMxAAFd5odgNK0WwsA5k+ywJCZG6uVUAsfc4zXD6L4Z1HWL+2vfEFmlnBDNFciGVhLO8kZLxjcC21VYg/eJPlqMAAl+u8XeIbTwvoU+p3yTSqhWOK3t0Mk1xK7BY4o1HLOzEAD3ycAE0ATeItd0vw3pFxqmu30NjYQKWeaVsDp0A6sx7KMkngAmuNOqeNvFxcaBaJ4T0c7lXUNVt/NvpfRo7UkCMZDcykkgg7Kt+G/CNxe6rD4m8b7LzXQubWz3B7bSlJzthGMGT7oaU/MduF2rxXc0AeZTfCG1u3abUfGHjW6umbc0p1Yx474VEUKozyABxUUXwr1bS1aTw78SvGMF1t2qdTnj1CFf+2TqB+or1KigDyubxd4w8DSf8V9pcWr6CDg67okLFrdQOXubfkqoAZmdCVGAMEkV6HFLpniTQi0EtvqGk38LJvicPHNGwKkZHUYyK0a8m1fR2+FOpt4j8MxSL4PnkzrekRIWjtFPW8gQcpt/jVRgrzj5QQAZXhfWLPSLLRnvJm+12lxPpsstzOY47g2jvDuMhYrFceVErlHKrIGPJxler1nTdFitNVtPDzXXhTUbmVLr+1dO04iOWQAOjswQxyoSTuQkbvmBxnNRX/g25F7qOseDtQtVttWkS/MKHaPPKgGeOUblO9VQ7Spydx3gOwPKwaSND0u00q98HT2OoyyS7tQ0zTvMsgrMTuZIpj5Z5/iBUEHC4wKAO48P+NJtQ0+y024l0hvGE0cha2s52mtsRsVMwcDIjYbSAfmBcKeQauakNbcW0eqWVjdYmWSB7K4aJ0lX5lyrg5XghiCSASdp5I4bxZe6fJqXh+4triy0//hFbiOW2vrq5W1Mlu0SpJERKirtcMFJQnBA4U4rbv9Tni1qC98T+JrLRtKt7tXa0e8icBwDhJGEabFyOrs2TgdSKAOti8WaWh8vU5W0m5H3odQHk4+jn5HHHVWI96r6lrOha4YtJgupNSe4cBk0u5bMajq0kkbDYo92G7oASQKzpvid4ca+ezsru21GYcItnfWsxk7fKgl39Tj7ta1v4iW2sI31eAaddTRtNFbS/IAvO1GlPyB+ORnjP4kAhPhC3i1jTb63nnmjsixS0vpXuYkLYBljLkskoAwGyQFZxgbiR0k8EVwqrPFHKqusih1DYZTkEZ7gjINYP/CXacLEzOJYrkKGFnPsimf8A3N7BXH+0rFTjgmsC/wBS8Ja7KzzSazdPcExi1V72OKZlHKBMrETjGQeO59aALGu+JNFuLa60TT7+1t4XeS2vLhI32QA583YwQxmTJIOWAVjkhsFT0PhOC+tNHjs9RETfZT5EE6SbjcQqAEkYBQFYjqoyO4POAttqOk6ZpNsskthpdtFEoWAyxxpAoH3ODtAHTjjjimaP4m03W7xotGeS+gRSXvYEJtgRj5RL91zyeELYwc44yAbVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGD4zuDbaOJBJFEfNXE0l8LMRHkht5BB6fdIIOeQRkV5ppza15lydL1+eSzyBBDYaU9/FE6k5MczIkWMcYXAHYV6zr1i2oabLFAIBdgbreWaMOIZMECQAg8jJIrzjUrh4bvyLsamQ9yI4LcmR2GfORAmeVJhtWAYH79wXzwCADAu38QSyzRX+ueLru+jkUPa289nYMFwMkJF5jEAOHbHOORnGKLnS77Rhf2r2V15DbvtEpurohxjOXlj075wOeS5xzzWtq+pv/Z9zpSTymWGSDT2jCOIzczpOhWIAf6lWZF44Ajb0ybkupTm81C7tGuRbfZk1a3+9sEO22dEyBhdxiuFwe3txQBwltoumxRPqGn3Xh9vJV5ftNpqOoXCR7GiDu06zIqhPOjZmA+Vdxx8pFSW/gObVbHxDdW9joK64to0pSY3ckhuVWRRueW5KiRJlkUSkHjDg4bFaWqnTYNS1PSdRs0W3n1do7G0EhhjnjjiJkEbBdrNIpe2aInG1Y+OdxseLL62/4V94lsL6S10kzaXLbT6hcCQsXRFRA/BZgxEqZALZTox4oA5e18P2WnaFBb674V8P3AtbaF7/AFKPVp7MvOixMZHkjQ7yVl80ODztcYyK6C28PeHrBtLi1Dwh4j0i5sDusptO1aW+ayEpZQ6xeYXG7axx5ROA2QNpxsRpp17dWSQWcEehLDEotlu3iYqtxNENu75TGonQ7PlwHQA4AU5uq6lfvqEkN4beKW4u54pYIcsY3Yyw7VkfBZmCxfOcERuioEDcgHb6Dc6zc2Ed94V8T6b4n00kDZfhY5Bxnb58K4VsEcNET61jTX0158R7fUPHdq+h6RpUSf2THcTh7aa8kVhJO8iHywyrlI1kO7DswAJwKOraxJ/b/hrxDYSwWy3l7DZSi2jG64RrjyDHJ6gCSF1znbh8feFao/0HwnPeWNlbaRNqOq3V7eyrdK9sqeYyNPNISY8GNY2KnvkAZBwAemqwdQyEMpGQQcgilrwzRPCmo3N7bajYOLDT47u2nhvI1OmQyqsqlgbccyBh8oyI9xbuCM+50AFFFFABWB4i8TeGtOie01zVNOU3AaH7JJIryT5+UosQyzk5xtAJOelee+O/Cms33jvUL+Pw5aarpU9vbqJDDaTzhl8wMqrcEYHKHG4Dr3JrV+Fs2kWeq3emJA+l6qIxixurCKxlkQE5dEQ4lQHjeuQDnmgDnPhNqvim1+Fmm2kX9nWNjpTXFtPrmuSkKsUU8iDbbgqw2qqqRK0RXHQ1PqM0UNu1/rWr+NNfAidvMin/ALIs2KRvIwjVDEzjYjEEmQYH3qo67NPqGoaZpEl7Z3treavq7wRQWRWJ7qK4AgilAUAmMmSRiwIcRlstjcdG8t11me5ljuLyW1fCQO13JtVp/Ks7eUjOGJjE8pGBlZUz94GgDnfEei6Je+H9bttT8O6Jo0K29wjX948uqXkJX7QGkTKghgLWVgd/O1fpWiYbKPTLa40vTvBl7C9qLkynw55fmwmFHG0GXJLGW3XBH/LX/ZIq5qv9kDwpruo6pp8l9E+kzzwqLmQSlWtbh2jdiSFbyWUlsHD3B45FY2n2upN4c0q3024iFq1rZ21itxEDPtjC4DyAqp2TT20eQqlmiyRhaANe306wSK6uf7N8Fp5UE052+GQplVZJEUAmYZMnlsVHcA1TvNMRdRWJfDXhNYG81GkGlSWzkxTNDIAEkY5LGHYOr+cuOhoKWjWN2t3eR/ZFzE+oNJ5DpaJNIqokg2qi+Q1uuE2sfOBycmpNN1O5gsxBcrczat5kzQIFcmeOFisFwu/cvkoHeTDMCH8pevUAvadbO94mnW+k2mXKiLytf1C2hkY+dwqhGAOLd29MFefmFOvGlhurjTrrTtTlktommmt7XXxdLGq7DytwFGSJFwMcjPNVtEF7HfWmpWPlLY/YJpbWKNMyOUltYnkDMSFVIFWJeA5/eMwBbFSWSRqNQuNVnuDNqSQgzxuzFQB5qqQ/Ty7WCKSQHq0jAHLCgB+mm3dVnttN8U25XyyCLTSC4MgygBAJzz26HrW7a2Ftcuo1bRfGl75jAP8Ab7wNF1/iiSbyyP8AgNYmkPfWj30d4txp0RcTC38wea0KRpGjkgquCqFmLFYVZyuJGJ2+n+G9XtdZ0yG4s5jMpQEOxGZFOQJBjGVbBKtgBhyOCKANUAAAAYA7UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeQWuo3VrrkRu7XUNQdZprNWaRW84JJLEGWTcAPmniQkgYLMB92vXnZURndgqqMkk4AHrXk0siTJG+mzHWFszJLbjTreWVJZDcmdVMoXYADHBn5ufm9sgFa5fStSmka0Fvc2q2gkOnfwW8xjui7EAgnP2ZIwD8uxflGCc1pLHT1aCSy0qwsFUCMXWnA2crMJriEAvGVLAOLc7ehLHHUCpNRaTSLaSObTIrKeL7DDZXOrX1pao0VthhvId3+dmmBG3o/Yk1j2iX8Y8uxm0q/it2H2aa2a81IJFugJV1gt8E5tomyrryWOOaAOu1iaL/hEWtry+s30tLhhOdSZIxdFgksKyNhFK7XDNkguVCEncxPJPpPhO/8E+L7aa5vY9NWxL3d3ayTSqrW8xk/ds58tyrg5ZfvuZSdqlRV+503xJc2saHznRW/eGPw9KqzxeQsLwOkl2C0bKoJBHXBGGANQQ6LrktvLFrT+JdQWSFoZI4tFt4vMV4wkygtK2BNtDuudpkAcYNAHV6xPp9pc3UenWFjBZXaNNOjxoPtQmCNK7ZBARwipnjOJXIIi54zXdPtYrFLTxJrl+kl84jgBgjN68gMZHkgRtO7rGgz94gyRRsxKMazNI1/T9U8MaLqVronxJv7V4V8uz0q1hihheM7PL8+BInKoYwoIPRRxkEDZ8G6XpP254F1HTPBjS5SSzs1lTUrkMQxWS8ukWUjOSRGoOeQ9AFzSUTTPEMdxfWM8+toWudH8LwTJLcozL5T313IPkjZ1IB58tBnbvdsVa+G+mwR6h4i0rW7SGW58Maj9otdJ0+RpLWAXCi4R0R8F5NzuAz8KVOwJzXp3h3w7pPhy1kt9FsY7VJXMkrglpJnPV5JGJZ2/wBpiT71yvikv4b+JGgeIE3jTtXUaFqIG4qshYtaSFVU/wDLRniLEgDzloAv+JdWlmsLdrjStRtbGK7gnuriUR7YY45A5ZgHJ2gquSBwCScAEjr1YMoZSCpGQQcgiue8WSztfaBYRXE1tBfXjxTSQttcqsErhA3bJQHjnCkd6qaJfXmp/DyPy7yJNWm0+TypmYJkgFVl4GACdrZAxzxQB1tFcx4KnmDajYXon+32UiJOXu2uUYsgYFGYAjg8ggY+mDWND4p127kgFvHpka3S3rRb0kYx/ZpQnzYYbt+e2Nv+10oA9Arm/iHBoz+EdRu/EdtFPZafC96GYHfE0akh42BDK47MpDZPBFYJ8a6pcQJd2drZJb505THKXLs14UUfMDgBDICeDuAI461g+Ib658f6vZ+A7qKKSKG8a616SKJhE1pBLmJMNnBmkVRgOWAjc8igCDw5p3iS2+HWj/8ACV2A8QWV3Al9dGytvsupWEzgyM/ljiZgWwxG2Qnd8shYipJIW8S+FbqHQrldcto7hp/tdhMba8W5AztvICU3E4AYAxtjAVEwuPWtQv7PTrcz6hd29rAOsk8gRR+JOK8/1+58Ha/em/srbVL7VkUxJqWgW9wspGM7ftUQCMv+yzlc9qAOW17xBprm60/UHjMt5KdJbS/sxtp5reS6tYcLG5VyXhfG8HoilcbTWgdQjtjFG1la2Iit/OikR8wPEtzc+W3zMFSLYPPZyWGAOCVUHkPG+vaoNe0Xw1qujr4ijgX+20h8T3NrYSwCMmNHMkUnlyDLONrx54yQ3JVU8UaXBKxXw54V0Ut5bsLDxvbw5KY2AxqFQ7cDGcgYGKAOxsL63Fvbh7L7Hqwkht2infyzHO8eUQuYvl+QFlRGQhSuVRjil8RNHrHifT44Zmgs9KtJbUSzM8cd1JJtLjYc+Yo8jA35UPuLbtgVuQj1vS7uApPqcMLyJID9n8S6VM6mQq7MrOgJcsqtuPOUXnFSXvijRYb5byXWzDMGVt0lxo7qzhmbcViuFLHczE8AEueOaAOhuL7UdKuJFn0+CWW8Vo7pZLoBYYHcK8jSqGd5HbCIiKdzngDaVE184b7N9pZ724vDJY3Skwx/M0iAQS7WYRtMqwxMxyoEewBZJFWsiw17Tbi2gkgv9NeW2iMEQj0i6DkbNgIlt55MOAzBXAyvmPjG45cyW7W32S/uPDkUbxPA8Bv3015d6SIiJDNDhERZZNqZOWbexJySAbLX7PPJpWoXNrLrautqtyFhmZGf5PtMhBZl2sWWJWCElgnTcR23hvRlspre/wBE1FZdKu1MjxFBsdCo8loyuMbUVEGc5QDuMnkrXTTbTwXVxp2uRWibG3RRQXaNsuIpk2+S7OQPLKfcHDDGNvPT+G77Q9O+y2kOrXYkS0t7GO31AvExEe4KwjdV+dt+GIHO1fSgDrqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEIDAggEHgg1xPiXwneatq0hhFqti4BLXl5d3ClsYKi1WRI1GMc7jnJ49e3ooA4bSfh3b2BdotTltTJ99NMs7WyU8dmSPzR/38z71pyeCdIljeO4l1mdHGGWXWbx1P4GXH6V01FAHKp8PfCik7tFtpO370tJ/6ETUieAvDEbq9tpEFrIp3K9qzQMD67kIOfeumooA8Wt/D8fhn4gTeG5tR1XSNC1j/AEnQprG9kRY5wCbi2cOzAsxPmgsvOWAPG0dxP4Z15Y2ig8UtfWrLta21nT4biNhjoTGIm688k1reMfDOneLdDl0vVkk8ssJIpoW2TW0q8pLE/wDC6nkH6g5BIPO+E/FN9p+rJ4S8dyQx68FJsdQVRHBrMQwN8Y6JMMjfD2J3LlTwAZ40nWtF4tdHubNACfM8NXkbRE9ObS5ARf8AgG4+9XP7NvvHHh/xH4f8TQ3CadPBHFBcT2YglEhBYsAHZW2MIyCMfMCOcZr0GigDznw34osdX8KTWXj2C0/tbSrqPTtWgmi8yMTlgsc+0oMRy5V1baFG7GflJru20ywb71jan9wbXmFf9SesfT7nA+XpXFfETw3ei7bxN4bt1vNQEH2TUtJmw0GsWXO6FlPAkUMxR/cq25WwKHw/8cWf9nQCa+N14dlcQ2OpzN+8tX4/0K9ySUmXICu3DgqCd5BkAPRdN06y0u3+z6bZ21nBuLeXbxLGuT1OAAM1578SPiZ4G+HSeVqRtptVjV/K06ziV5h5hDPntGGyGO4jd1AY11nj+50618HarLres3Gh6eIT5t/bTeVNCPWNsE7z0AAJJOACSK+Ql+FQsfGOk+JvEltdaT4GnmkvZ/7YkEtysMOxgtwAFHmTscCNdz/M3DbSSAfTV34is9C+Gdpr+uaBZW2o3cVu1to8K7nmueGtbZfkyZAQgGFO0qSBhc1o/DrwnLoWjXtzqzQt4l1mRrzVLq3Tb+9bOI0JJOyMHauTjgtgFjWZ4V0bUfE/iiDxt4ptJLBYImi0TR5gPMs4n+9PP6TuABsHCL8py2cei0AeY6H4A1KK3txdtpdtfwqI5dVaM6jfXRAx5vmTgCItySm2QDOAeK6Q+B7C53HWb/WNXdjub7XfSLGf+2MZSL/xyuqrj/H/AInutM+zaH4bhS88WaorLZQswEduoHzXM5wdsSdcYJY4VQScgAxPAttpl1448Y2Nl4e0ODRdIktbO1uLWzjBkn8ovOrMOpXdGCOMfXNejxwxRLtijRF9FUAVi+B/DVt4T8OW2l28slxKuZbm7lJMl1O53STOSSSzMSeSccDoBW9QAUx4Y3OXjRj7qDT6KAMi/wDDGgagxa/0PS7pj3mtI3P6isv/AIQDQIlddPhu9NRgR5dhezW8X/fpWEZ/FTXV0UAeex/D6XTLl59Gu7fczbn/AHP2OaT2aW2KK2O2+J/xrrdHsNQtGVrzVZ7tDGA0UyRsUfj7roiZHUcrk8HitWigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKyvE3h7SfFGlPpuv2MV7ZsQ2yTIKsOjKwwVYZOGBBGetatFAHnUdv438Gqsdq58a6IgVVS4kSDVIVAUf6zAjuMAMfm2OSerVo6F8TPDGq3K2Vxevo2r4QtpusRmzuVLZwAsmA/T+AsPeu0qhrOjaXrlqLXWtNstRtgwcRXcCzIGHQ4YEZ96AM3UPFlnp7ypc2GuMY2K/6PpVxcB/QqY0YEH6/lXnV3aTa54nvNZ8JeEdTtZr23ktNSl1w/YdOvF2EK89sQ0s5XJA+RMhiC2OnUQfCPwfZ3E8+kWV7pE0zb3Omalc2q56cJHIFH4Cm3Hwk8L37RnXf7Y1tYpBJFHqmrXNxGhHojPtP4g0AeW23iDTYr3S7+5aDxRr2nFYGsJGhi0vRW8xhCY51doIT8uAWMszbUA2HK10/9keLx4htNf1LQLPxtqSRI9tcDVI7WwsGJLMLWIqxJBwDK/wA7BVxt6V63FoulxaR/ZMWmWSaXtKfY1gQQ7T1GzG3HtiuI1T4H/DjUp3mufCtojOdxFtJLbr+CxsoA9gKAOB+M2mfFLxH4B1RNR0zw/HZIYp4bPSlubzURKsi7QhAC9ySwHC5rzDwZ4G8WaPcQXPjz4gy+BrCRfONvJrJjvbiPgnZGH4yMjn5gf4D0r6Gb4D/DhynmeH5JAmNqyajdMBjoMGXGPauo8PeAfCXh2WKbRPDmlWdzFnZcJbL5y56/vCN3f1oA5Dw74i1LUNFsdL+Gdjf3lgqKW8SeIzMImDEMzqr4muHOX6bEBwNwGBXXeC/B9t4cE93cXU+q6/eAG+1W6/1s5znaoHEcYJ+WNcADHU8np6KACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKAQScHp1ooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAiubiG1hMt1NHDEOryMFUfiafG6Sxq8bK6MMqynII9jXl/xW02WXxh4Y1LVNEu9e8M2qzrcWdtbm52TMAEkaH+MdR0OOfXnufB6WieHLMabpc2k2mGMdlNF5TxAuTymflz1x2z26UAbNFFFABRRRQAUUUUAFFFFABRRRQBj6Briaxea5bxwtGdLvvsLMWB8w+TFLuHp/rQMe1bFcB8HrdxY+KdReUSLqXiPUJ4yFwAiSeQo9+IAfxrv6AOR8T6xe6J428L+ZcIND1V5dNljcouy6KGWBwcbjkRyJjOMsvGa66uF+NaSx/Du/1K1hSa60ea31eJXHGbeZJW/NEcfjXcghgCCCDyCKAFooooAKKKKACiiigAooooAKKKKAOVvoBrfi7UNKvZbyO0s7G0uovsl5NatvlkuVbc0TqWGIkwDwOfWpf+EL0v/n68Qf8Ag/v/AP49RYf8lJ13/sE6f/6Ovaf4zur6zj0mWxuvIRtStoZ08sMZUeVVK5PTgnpQAz/hC9L/AOfrxB/4P7//AOPUf8IXpf8Az9eIP/B/f/8Ax6rnifVJ9Nt7JLRYvtN7dJaRvNny4ywJ3MAQTwpAGRkkDIzmud1rxPrWmXN9CI9NmOnWlrczkBwJjNPNGVXk7MCLOTuwcjB6gA1v+EL0v/n68Qf+D+//APj1cV8UPBeqW+nWuoeE9W8TIlq7G+tbfVbqeaaEjloleX5pEIyEyNwLDltorv8AwzqV3ey6xa6gIDc6deC1aSBSiSAwxSghSSRxKB1P3c98Vx/j/RZPGHi+Lw/cM8lhFYfaJIVuriKFA0nDzrE6GVmaMLEu5QoWdyWIVaAOM+BWi23imXxLrcXiXWr7R21OW3gWO/u7czlYoNs7ESh92MjDDOMdAAK9XTwfpEhYJe68xQ7Wx4gvjtPof33XkV4jpvw28K6LN4g8Ratp2k6Zp+i6hIss9reXySooij+WEiVMMzMQBz8z7RngV7h8ONHbQvBmn2Uk+o3DnzLhpNS2/asyyNJtmKkgyLv2sQeSCaAD/hC9L/5+vEH/AIP7/wD+PUf8IXpf/P14g/8AB/f/APx6ulooA5r/AIQvS/8An68Qf+D+/wD/AI9R/wAIXpf/AD9eIP8Awf3/AP8AHq6WigDmfBa/Z7vxJYJJcyW9jqKwwm5uZbhwrWtvIQXkZm+9I3fFdNXNeE/+Q940/wCwtH/6QWldLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRVDX786XoWpagApNpbST4bodilufbigDjfgJObr4WaVd7XVbqe8uUD9dsl3M6k/gwNeg1yPwoUw/C7wWixNzpFpuxgbP3Ckk5Prxxk5P1I66gDG8a6cdX8G69poEhN5YXFuBH94742Xj35qD4eajPq/gHw1qV44e6u9Mtp5WAwC7RKzcfUmugry74U+ILbQvhX4Uh1ud1LXr6FA/lk7pEuJYYgQOmRGBnsTz60Aeo0UUUAFFFFABRRRQAUUUUAFFFFAHNWH/JSdd/7BOn/wDo69rX1XR9M1dY11XTrO+WI7kFzAsoQ+o3A46Csiw/5KTrv/YJ0/8A9HXtdLQBXu7K1vbRrW8toLi1YANDLGHQgdAVPFQR6NpcULQxabZJEyLEyLAoUorMyqRjoGZiB2LE9zV+igCndy2OkWeoajceTa26q11dz7QuQiAF3I64RAMnsoHasH4d2Vwujyazqtu0Os6zIb25Ei7ZI0OfJhYYGDHFsQj+8HPJYk7eu6Ta65pcun6grPayshkQHG8K4bafVTtwR3BI71wnxV8SXdrquneG28MavqmganDKNXvLWynuFSBlZfKTycMHY4yc/KvZs8AEPw/s77W/EF9rlpq9rN4Pkvri6tVtD5n9oTFvKLSl1G1IvKwoThm+fcQFB9QrxfwD8QYNJ8L3UFv4U8WT21pf3wj8rTvLiihF1L5camRkAEaBUK/w7duOMV7Bpty17YW9y9tcWjSoHMFwFEkef4WCkjI9iaALFFFFABRRRQBzXhP/AJD3jT/sLR/+kFpXS1zXhP8A5D3jT/sLR/8ApBaV0tABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcV8abiaD4W+IorWA3Fze2/wDZ0UYzlnuWWBenvKK7WuA+JbxX3ifwDoLTTI91rH9oOqA4eO0ieX5iO3m+R+OKANnWZYtDbwlp1jaR+VJfLZQKcfuUW2mbIzznZGV455+tdNXnvi/7Vd/GH4fWls+ba0i1HUbqP0AiWCNvznYfjXoVABXyf8d7zUdI+HerwLM8M2nePXktZE+V0WWBrtTkHqHnJB9MelfWFeQ+OfC9lqPj/UdJvI7dI/FekSm0mkLHytQgikhLhehY29z9cQ+wwAdp8MPGFp468E6ZrtpJEZJowt1FGf8AUTgDzIyDyMHpnqpU9CK6quQ+EupQ618PND1SNI1uru1jN4yxeWWuUURS7h6hoyvPZQO1dfQAUUUUAFFFFABRRRQAUUUUAc1Yf8lJ13/sE6f/AOjr2ulrmrD/AJKTrv8A2CdP/wDR17XS0AFFFFABRRWH4ovZ0gTS9IvrS012/VhZm4UuFVSvmShB97YrZAOAW2qSN2aAOQ8GaNd3kN1oXiLQ3XTLW/n1JpJ52xLcSXklxEiquFlREZGYkld5AAJVtvoWo/a/sU39mmD7YBmMT52MR/CxHIB6ZGcZzg4web+FN1cXngPTZL27ubydGmhM90QZXEczoC5H8WFGfet3XNTTSrBpzGZpmYRW9upAaeVuFRfcnueAMk4AJAA7SdSi1SxM8CvHKrGOWCUYeGQdUcDPI9RkEEEEggmh4O1K91TTbmTU1gW5hvbi2IgzsxHIyjGeeg61P4f0p7C0ne8dJdSvXM95NHkBpCAML3CqoVV74UE8kkv0PQ7HQ45005bhVnkMria6lmy5JJI3s2CSSTjrQBj3Xi2aHTtV1RNMMmk2DTx+aJwJJHhYo+EIwF3qyg7s8ZwBzUaeLrqPUHtrzSVhWG9hsZ3S637WmVTGVG0bh86hs4x23Vpz+FdHnN6JLeYx3m8zxC5lWJy/3m8sNtDHuQAeTzzUt5pWkC4Ml2kaTXd3FON8xUyTxgGPAzyQIwcDrtOQeaAKPhP/AJD3jT/sLR/+kFpXS1zXhP8A5D3jT/sLR/8ApBaV0tABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVWv9Qs9PiMt/d29rEP455FQfmTWKfGvh9pjDaagNQlAyU06J7sj6+UGx+NAHR0Vy48R6re7RpHhfUGVuk2oSJaR/iMtKP+/dYmo+ILxSV1bxboWjKH2mHTkFzPnPQPJkZ9vKNAHodUtT1bTtKj8zVL+0so/wC9cTLGPzYivN01HwlfxsxvfEHiGNQHlmNzP5WC20HYGSMnd8oVVJyeBV3RvDsOqBb3w9pGl+HLAlTFdNpkb3046lxu4jHYFg5PXAGMgHRL478OTPtsdQOotgtjTbeW849f3Ktx71Xl8cxAn7N4d8UXKjHzLpckf6SbT+lTjwjDJIX1DW/EF5Ix6nUpLcZ9lgMa/pWZ4h8B+C10i4l12Mw2q4eS8utSmV4+fvec0m4c47+1AGlZ+NLKWeGK707W9OM0iRI95p0qRl2YKqlwCqksQBkgEkAdRXKa1raQ/EnxVrbP9ptPBvhwlrTbg+fPunfD44Pl28I/4HWhpejeHdJ8JJr2qQT2drYBr93Ek8KskTFkleBWALFVV9hX7x+6CMDg/FGm67J8B9VjWxvP+Et8a6iJ/sQLMyNNIpWIkgbAltEA27AXa2TQBP8ADTx1oXjf4v33iSK+SEtptvo2mWJfM8pYfabhmi+8NjAIXxsO0/MeK94ryn4DfCOz+G2jtcXZjuvEl4gW6uV5WNcg+VHn+HIBJ/iIBPQAerUAFcd8UtOvbjw9FquiwvPrWh3CanaQoxDT7ARJDwCT5kTSoBjqwrsaKAPOvh9qVtbeIbyzsrjz9D8QRnxBo0p3ciQg3MXzcjEjrLggf69hj5TjX0jxjNf28rt4e1IPDNJBKsEtvNsdWK4IEm4Z255UdRXKX2j2/hjxdYaXdkWvh3UtSN7o13DKUfTdRIJe3w2V8qcGUqowMvIm35kIv+P9C8O6l400xPEuki/tLy0kBeOJswPGyHzJGTDbCGC7idq4HQMTQB1yeJrMrmS01iNu6nS7liPbKoQfwJqKfxhpFsM3LahAucbpdNuUH5mOuJ134aeE7ezi1jRbQW8KBD5ljdvBshzkvG8bKTj73LYxnFGo6RC0wfwtq3jMtGsYWa21Ka4tp8ttbJn3oAgAYlOeeA2CtAHcWfjPwxeOqW3iHSZJWOBGLuPfn025yD7YrfByMjpXmyaX4knt7uWDUvD/AIz0crm1j1KBFml4OUaeIeXwQMfuud2CRjJx9Cg0TVtHsdQ0LwNfaNe3LNFLBDLLpQhmTPmRs0ODnIOGKhWxgkNhSAew0V45p+s3FwTPocvih7ZHaJ5LK/jv4Q6/eQmdGOR6Eg+9bGleKtXkYI2pWSsZNix6rYmAlj0UzwyvFu9FwCfSgD0uiucTVfEEaq02gW1zGR96w1FZCfwkSMfrTW8UXEZxN4Y8QRnPaOGT/wBAlagAsP8AkpOu/wDYJ0//ANHXtdLXF+HtTjvfiNq+6G5tZ5tGsnWC5j2OFS4vASeo/iXv3+tdpQAUUUUAFcBrHhDxRN4tvta0fxZYWX2iFLeJLjQYp5YI1O4xrMHRmUsS2Gzgniu/ooA8J0dfHemfDUajp3iaydmlmitrKDQVaSWaS4ZEwxnCjLNnJGFBJOQDXtllbyx2Vml/Ml3dwooe48oJvkC4ZwvO3OTwDxnFee/DHQ4LyS01qHV4NV0axE8GkmGJkUSPIwuZWyPmbeGjQjgIDyd5NemUAZPiuK8n8O30Wm28VzdOm1YpcYcEjcOSATtzgEgE4yQM15tFpd5ptzYWeoaTe3VhcazK9vp7NbAvD9gGQURliCiVZDtz2zyTk+v0UAeTXHhrxIV0hZLN5LqySz8m6geBmjCzbpUklkPmYCcfIPmHUnJFXrnwfO1nb3d1pk19eJrtzdzQm5DM9uZbnytm9wgGySM7cr378V6XRQBzXhP/AJD3jT/sLR/+kFpXS1zXhP8A5D3jT/sLR/8ApBaV0tABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGN4os0urKMto0Orsj8ROyKygjkqW4z04yPrXLnRrAMpm8Gaysar2vEcDnhVVZz/IAV6DUV1cQ2lu891KkMEYy8jnaqj1JPQUAedwWEz3Un9i/D2xsEiJAu79IPMZv9lFbJGe5ce2anYeNNR0u0sbq4ttLubguv27TYW2IwXKq8UoLAZVgSGGQRtcEjPa3Orada2TXlzqFpDaKNxnkmVUA9dxOMVQ0jxFY+IbYvod2rBixilkhbbMisFZ4wdu9c8bhx0IyCCQDhtT+EkGoQN/a+o6jrxKEmHU7+d4y3YBAwUc55xxxxW94e8KaPNbzRNo2nw2NtO0Vsoj/ANIVo/k80vwUJwcBcfKQc/NgdhbRTR7vPnM2cYygXH5U3UpzbWE8wmgg8td3mT/6tQP73I4oA5zSfBNiluv9upFq0wkZ0SeNfIhBbICRABARxl9u5jkk9ANO30XRtEea/toINOVI28x428qJU6lmXO3jGckcVmabrOuaxNKun21jHaxqP9OlWUo7kn5Y0IUuAACWBCncACcHEa6db6nfeT4k1Z76SKTclkQLe2cqQQwjBJlAI6OzgEdARQA6Xwl/aiyyalqPnGUIVmtoRGXAzgyKxeN26YYIpGPSrWjeDNG02VJ3tYb69jk8yK6ureIyxegVlQYx+fNTeJPE1ro01nZIrXer3zBLSziDMzZIHmPtDFIlJG6QghR6nAPPWHhWXxZoN3beP9Yt9eSaZGkstNLW1payIuGiUo3mSDcTnzWIOF+VcUAYOv2X/CT6nbeE7E2s/gyTUlnvrjz0dMxqJ/sCJgk7nUSE5AVMqD0WvXa4zTksJ9cs9F0HT0stP8P3DvcJFbCKGORoj5caYG0lhOZDt5XA3YLAV2dAGVoGtQ60L4wwXEH2S5Nq6zpsYsFVs49MOOtMuvE2kWs93FPdhPsiO9w/luY4gqb2BcDaGC/MVznHOKi8NaPfaVdarLe31tdLfXP2kLFatCY22KhGTI2RhB6d6zdQ8J3dxpfiDSoNUhi03Vkusq1oXliedGDEPvAKhmLY257ZoA0ovFmiy3KwLeEStKsO1oZF2u2Nm4lflDZG0nAbPyk1u1zWpeFvtt3fzfbNn2q7sLrb5Wdv2aVJNvXndsxntnvXS0AZ/iHRdO8RaLeaTrVrHd6fdp5c0MnRh1BHcEEAgjkEAjBFeYQXGueCvEBXUf7S8XRaTpbKXs7dX1CSGa4UQBlLjzWUQSh3XBOUJUnca9frivGr3uj+JfD+s6bteO4m/s2/hMe7zISryIynIw4ddqjkEy4xnFAFHw5qvhTV9dkgsLO3024uYSbfzYDZXbzZkE6pG4V96BVLFR/H1rpLWU+H5UttW1Wa5t7qYR2ctxD80ZI/1ckqjacnhS2CSQuWbGeK8bW+m+K2s21bTdN1C1lj87SHuI9gvLeWNfMhSR8GG5yodGBUkBcEYkK9NqF+NN1LTPDWo6Zc3Oh39p9kTUZpmnLzAEeTMCCfmQZ8wsdxyDzgkAvW2q+Xba99m0zOoWE0jSWkBUPcZUMjg8ZLrt5P8QK5+U1q6VqNpq2nwX2nTrPazLuSRe/Ygg8ggggg8ggg4IrjbjQ5dDsrPU9X1jVry4hVIbq9V40eCLB3FikaeZGGIJLglQWYEfNnpbfQ9EmgnmhsbKZL+EJNNsVzdRkfxt/HkY5JOaAKHi/T7eWN3sgq63PGfKijuDbyXix4Yx71III/hf8AgLA9CQ1LUvD2p/bLC+S8e8nCy21zbz/6m6RwFUyjO1QqjcyouGbptBNSXOlX+g38cnheBbn7SQr21zhYkRcZzPy6dSQMSZJPygZYN8R2epzX8MotNaulaIZisNTS2hgbuAco7nPdsj2HNAFZPh7bnT7XTXktoNNhLSNBawsqPITjIRmZQFUKBkNzk9eajh8C/wBhXLz6FHFdWphZXs55nhd3PBIkQ7SCpI2sh5wQVrQtIrK/ktLTW4tZt9QhDLBJdz+U8gPOBJAwRjgdM7sDJ7mppfDt2uoQBtU1W70vGzyDeNE8B5O/zE2vIDwMOxx1HcUAY2habDpfxfv7az87yF0C3I86d5iD9pn4DOSccdM4r0KuMtVH/C5NSOORoFqM/wDbxcV0F5oGk3ss0t3p9tLJM8ckjNGCXaP7hPqVycUAadFY1x4X0S4WdZtNt2E9yLyX5fvzDo596bN4V0OcagJdNgYahIs11nP711+6x56igDbrmfF8t3d3NhoFrptzc22prKl/dK7Qx2tsFwx8xefNYsqoq88s3AUmqGpr4fn1C/i0/S31fVJ5opLlLVjtWSI5QySkhIypAyudxH8LVzmq/B7Q9ag1K88Tx3BknSWQQWup3bpA75LOC8mGbk4+RV5wVNAGT8DPGbyeCLTTtI0jUNWjtWmijNqgVIQJWO15ZSsYADKFRWdtiqxxuwPbq8B8H+AvC+h/DPwsw0/Vr3VdW8iNYINWvLdZ5pBvdiI3CoqoruSV6JjlsZ9hh8JaNFaG2FvM0JtVsiJLqVyYVJIXLMT1PXOT60AbtFY8vhrSZTJvtT+8eF2xK4yYhiPoeg9Oh75qZdEsFuEmWFxIlw10D5z48xhgkjOCMdug7CgDSorKm8P6dMkiSRTFXuTdti4kGZMYzw3TH8P3farllYwWT3DW4cNPIZZN0jPlj1xuJwPYYFAGH4T/AOQ940/7C0f/AKQWldLXNeE/+Q940/7C0f8A6QWldLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBHcTx21vLPOwSKNS7sewAyTXHTTHxjfhtD1K9tLGyYx/2jY3EJWVyqMVClW3AAgHOACDwcV2F1OltbSTSPGiIpYtI+xR9T2HvXLr40t208yCXSBeiTaLb+00bcuOoKKxJ68Y7UAT2vgvSob+K8lElxLE+9PMWNQG7E7FXP45rZv7K11SPy5WfMT8PBM0bxtjsykEcHpnoa5PVPEepXglgsbCRrVif332KfLR9x+8ESKSM/N5hA689K5e51S3m1ATwPM7w/KIZtXj85+oCFrSOWYgZyMv1oA7i6j8Q6LZBdOaDVYVc4E4fz1QknJYufMI4HG3j6YqOx1/UkmdtQtLqcMuI7e00yZCp9WkkIU/TAx6muIbWNUj1ayitZ9Uhupz+7to7W7mYg5GT9qmjUAf3mTGenNN1XQ9X1SK5k1rUtYubCB9txDea/DZRHcB8jraQk4IYYUsSdw65FAHbrrt1eXttcXV1Y6Lo8f70rLdRST3QwQAdpKImechmLYx8vOZZF0jUYtRvYtKvryKBGmaHyWWK8baeEjchJGOBhsYJI+b08ommhmvoZLTwPHrkcQEf2uS4uZIbVB/00uQoCqOygH2p/iHw9D4jt20+y07wIsPnw3Oo3MNxMCLKOQPIBOIwELbQp5+6zfUAHSaVPZ3Oki/8R3umjW54yk1rYC0kksoN25LM5XLqnOc5G/ccdKfaLbXV/HZaLoniGeyMJlnuo725s/NcYULkNHHnp90kBRgKAABy6zaCstvcw6JoNslxK0CXWlahfacscqgs0cjww7Y3AGfnZRtOQSK29Ev5YZ7dNL8V6vpF1czeXBaa+yanYzScjyUnyJN+eiNMsnGdhFAHYeE7HxFo+hJZppej27GSSXy1vG2Rb3LlVCw/Njd94nLHJPWtlYPEMgPmahpcGf4Y7J3I/wCBGUA/981jHxZq2ijHjDw9cQQKMtqWklr62wFySyBRMnIP/LNlHGXrpdG1nTNctBdaLqNnqFtnHm2syypn0ypIzQBV0C5u/tep6fqNwLie1lVo5PLCF4XUFSQOOGEi/wDAK2aw7sfZPFthcDd5d9A9o+OQXT95H9Pl8/8AMVuUAFFFFABVLWtMt9Y0yaxu/MEUuCHjYo8bKQyurDoysAwPYgGsnXPGugaNOtrcX6z6g+fLsLJGubl8A9Iowz4464wO5FZLf8Jj4o4GPCGkt6+XcalIP/HoYOP+up/3TQBja1Z33hXTyNTmsbzRN37zztTSyWXvgxSIYwT3CSIp5IRelc1e+OtRFhqdr4Vtr+S3vY5pLeTS0Gp/YZzg/wCsgEiopY7hGVbO5sOuAo1rI6CiXGr+EfD8OrpaBvN8Ta1NJOrbOG8mRhJNNyDjywIyeFbPFXtD17XLvxFBb6/qzRK1wVWGwhSOPMYBeNsiVm2niRlkWNCypvLkqADNtvjAs/8AZViIb9fEccafb7N9IuhDMcL5hTbG0qgHJU7GyOGAzuXOHxU8MaDfxzz6WPD+oSbzLp92lxZlsk7XwUCkkcklOM/e4qzceHpvBCpbS3lz/ZZvLq6QRaldWsUMEk7vHBlWC7suDkB5XJ2qpALqtxZ3s12l3Zanq1jatCbm2hk1u4kXySrBZJd826WVh8ywoUVerucgUAdSnjWe40qDVTqOgaekxL29tcXayRXManDf6ShKhvQKGx3Bzw608e3yzPHeaPHJ8xKvbXkT/L/CCAxxx3JGeuB0HJHwNos0T6hqAin1u5G+OMwwXpbCLzcStC6l23bjjAG7C5A3HFOi2GmxRnVdN8JTIGO+W58NWvloCflVdkir/vEv+AoA9nGs3U1lJdXOkXVvaBcoVHnTs2fl2xKrd+5IA69OadbeIrKxgt7bxDqFpY6n5KPJHcSrFuJHVScK3Q52kgHjNeV6p4bsNIvLlLSDwib6B1ikSx0aW0CSOAyoZFuh85UghFDPgg7cc1a0h9YtbOQ6hc2mjzQx+c8UutXSBIyxUHbKzlc8YDIvJwAaAO20yWO5+K2oz28iSQyaBZOjochlM9yQQfTFN0vxbcCVjrWyBzEGNj9imhmjYuikK8h2TKpfBdMDoR1rH+HV3cX3jvV57uSSVxpNoqSOWbevn3XOWhiyM5wQpHH3jXSNo/h2Ca6spmuJp1tgWjmvJ53jidjjy9zErkx/wYI2D0FAElx4p8vxO2lRafczRQxzGedTGAhRYHyAXBI2zjPGc9BjJqjrmq6dqk2n2s1rql0J44pUs4JFjSYSpK6iTLqGwLeTKk7fmGc9tO20HQre9Z4y5u4C0spe+ld8OqA+ZucllKxJw2R8o4qDw7pHh3zDeaT5kxtHWJZXu5ZghjRwoUuxG0LPJ04+b2GACjb+NtJs2u7Kz06eO3sFkRVgSMIDHII3XAb5AGJ5OBhWOcAZ3INUtNV8LzahJLFbWbwyl5TPHIkajcC+9GK4wCc56dcHIFNrTw+04aK9lT+0XdUFtqMyRu+d7lAjhVbIJJGDkn1OfP8Ax54s8HQadfeGxrWgtpkUd2mp2d3fv9ouJwrbYdwbeCXyWfJI2hcHdwAdp8ONOEWmQajbarPfaTcWNrHpqENGi26xhhIyHH712diTgfKEAAwc9jXnPgXx/wCDLTwT4ftrjxZ4et54dOt45IpNVhLRsIlBUktkkEY5r0Cyu7e/tIbqxuIbm1mUPFNC4dJFPQqw4IPqKAJqKOe1FABRRRQBzXhP/kPeNP8AsLR/+kFpXS1zXhP/AJD3jT/sLR/+kFpXS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZ+updvp0n2GSFGALOJbY3G9QDlQgZck9uT9K80g1q81O1iP8Aad8Iyu6S2juYbcg85UfZo5iuOnMo5+letMAykEAgjBB6GvNNUTWrZ55G8PXiWyH5fK8QNawoo4HAfCjoBjA9h0oAyNTj0HTz9r1OWNYppP3V1exxybl27uZ7yQgOvIKggnaTtx0uxXs914ch1BdQvZbFJikctqG8ry3A2tmGSDeox94Lj5wF3Abi3SY7u6aSw1OW1sd91hfmMsZnwRsMuSxlztBDSBzhShAGGoQRacu06VFpX+hSB5CwMYj2qQ6LEiiSc/Njy9qIzIjDa2aAJY9UMlw1qmoz3ltIFmRgLoCLYCGMzsC6xEspEgdjFIFflcgJBFdpd24srWQxwTSJfERoChCZ8qRAyhGzKsineu1izRlo5MVGLCOCQXkaKJ7h8kks8b8H5SsZxKVGf3EHyAqd8jEBqbapaxsz2OgaXcNcyNKrx2VvPcBFVF3MC8atyAoaISIGYIM4ywBavlfTtOU6bBpl9PCP9FhtJkfygCo2vLJFKIwM468np7R6WdT8Q2WjSPeGyksNci1LUIV1J3226RSjaZyxEoLBGZQqKBkbRjJqfbJLye1uEluDGyM0M1xCv2faVUqQoRRE2xiysiO5GSXKIwEmixudQ8M3uuT6daXqak0okcSrFI0trLAkCNNIWuGLyKQ6BUZUYjtkAbrMeuWutSnSdcuIpIWEcttMguIwfMfyYy86tJnedyu+AxO2LP3abNerZWMqXkxZ7yzhgukmgt5POiAyEhRpI4AuHOwtGWIOCDgAaFkv/CLXNnFrt+3lJ5sK29zaq89xvBDLaQr5rMpIU+XGVVFxlSBis+8W0tL60N4l5o00ylxaQzvNrup/KSxENu2yDdhtzjcQCeYSMgA66w1SWPwnYXWP9Jtr6exiE2oMkabJ3i2yNkeaV2bQMMzMO+Sa5PxEU1vV7q3tdC0HWPEClfNfTtM82WAHPyzXMpRIXAX7pYv0ISuutNE1zWrW1spoB4S8NWpQRafYzD7bKiFgEeWM7IEIC8RMzEH/AFi8g9lpGmWOjabb6fpNpBZ2MC7YoIECIgzngD3JPuTmgDmPhl4c1Hw3YalDqEp8m4uvtFvA101y0KmNAwLlVH3g3yqoUDHUkmuzoooAKr6hbtdWFzbxzPA8sTRrKn3kJBG4e461YooA8nXS/EXhSJoJLOJtGiUKlzoQl8xVAA3S25LOTnvGXOP4e9afjy9k8TfDgXHhpZNV0t7iH7fFAGMt5YrIPtCQkEb2ZARgH5huUfMcV6LXLat4YmhvLjVPCl2ul6tKd8sbqXtLxuP9dEDwxxjzE2v0yWA2kA4BfttxM9xPdSTW1y6y2FpYyCK3ltgzi1ijIyFUqjSvKPuJggZYFLGmXempJD9pS7ksLSaGdpIrqeOBMOgjlMTSMo82YmRVYkCNBIxyVy29keHWY7b+zLLTru5LrN4f1bi0vmZ1dmsrtQVDOwDNER+8xlo4yWc0o7XT7HxJZO2lanYtHe+fBp+rC4fN07AllfzHhuZ3OQrGVViyrEErwAU7TSobe31G50HUbfUNN1nVdU1Q3aafunDOwjktkDH5YwYyHlZolOY/mAJzZ1O308eE7e61JbJ9Pmn+zv8AaoxIlxcMWZZgZIyJi2V+fbcDPEYwC5nsL6z1Pwhp99pV9qFtpV/dahcxzfZfNnFxJfMcyQndB5cbE43ZZiFEeGOGtXGmahZXD28en3kl+45iS5M8sgbOWSViSsJI6TELnOUY/MQCfw3fxT2yvZ6laRxz3jxx2Nram3llkkwW3RDc8eNnmbmAJDNuVFGaqa3p1hDqmJTGLzc5nmngmmeKFOXkWR127QcDMaDH98HrfsZry1httRgvEW2igFu5hgDzQKxLkLLMwi8vjBkGUYoqoo24OVcyC1YS3sV6161wkzl/L+1Shcg3e2QIo2sVAaQLFEo/d5OKALOoa4Cyano9lcQWt15hhlvbe4jMilAVYT7UECOyoxLy5fpjJGJtMvo9PttRuJLNni3xxQlZvKbzJIyzSiJFBiAwQjshkbO7cQc1U8O6nqc92YLK1u/D9z810UuEFyk0a7TIEAl824mcD/XOMbUKx8kueh1ae40+KOymiggFy/nDy7dFku5yNzsVCOd33sqkcjAKCXGaAK3wxnjufG3iB42QldOs0fEnmkHzbrhnLuXYDGSx3dsLjA6TxF4bm1DVb25t47I/a7JLUyy5EkJRpCCuFOQ3mYPIxt7545LRry9XxFrYtpJFvYrXSbRnYCR41kvbgNkF3IIRzw2CMAlQOK1rjUNet7F3ku57ncL2HaYQhHkz7I3ygB3MoJPODngDuALN4GuDfajKptpDNLLNHLLPIQ4edZTC8W3Gw7QhOTlewre0/Rr6DQ9Zt1e0tL2+eaSIwDfHAzoFXgqN2CMnjn0rlNZ1zUoNRu7z7ZcJPaJfD7Mbb91AquqxPnbliyANyxzngDBq/wD21qHlsH1S5j0zz5Vh1QWau8u2OIom0JtILtMMhRnywAcnNACaV4LurO+hvZLfT5HW9FyYZbiSYKDCI2YSOudwKhgNoHAHy4zXQ/EFgngPxK7IHC6Zckrtzu/dNxjvXP2eoeIL9hFJJNpkrQ3FxKEiEhSREt9sYLhgBukftzg4weax9a8UWmkeEvGeo+NLiaeweBP+Ja6sgkWW1iHlxkDcAzs6ZBwDuJxhjQBraJbs/hzwTb6ToWnzxzW1tLdXM0SeXawrEp4XIYu33UwCB8xP3cN38aLHGqRqqIoCqqjAAHQAVzPw90bStP0RNQ0m2eI6rHFdOZSGcJ5aiKLI42xxhUUDsMnJLMeooAKKKKACiiigDmvCf/Ie8af9haP/ANILSulrmvCf/Ie8af8AYWj/APSC0rpaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuR8YaCszSajFdRxHALxXEgSMuFZVdXIIR9rMpyrK6kqykHI6W/tftkAi+0XEC7gWMD7GYemeoH0wfevO31Oy/tSe20/RLeTUoGy3mo2o3UbdvM2ZWMnqN8ynHagCpbfZXuSkuo2UsPkeUI7GCS8f8A64vGgYeUMsNhZuvyeXxVCY+JLyIhPCutX8indundI4yxyeFnusY5xzF07V2Yg8U36/Ohtoz/AAz3aw4/4BArN/5GqNvBN1dEtqF7p8hPXNiZ2/76nkk/QCgDn7m5NxDby61pelaTqbovnefrsIVtvAU4jIcYAP3AAc49TWmb7faTrZ2tk0k7CV7+3mv72YuAQriRYRnbkkLnaOwFdxaeDYoFCtq2pkYwRAYrUH8YI0OPqanbwdpMuftJ1O5BBBW41O5kUg9flaQr+lAHBf2VqkkUSrHNPIp3STW+jvbs5PX5ri4VeW+fAUfvPnADc1zvjGz8Qf2dc48G6zrljbQ/ad0usWdnsaLMiMsdmA7ndkgBs56V6/H4H8KxqoHhvR2x0L2cbHpjqRnpQfA/hM9fDGh/+C+L/wCJoA8x8O2+kGzXVLybXrG0vIYrlm0PRJrRLqNkDK0k8IluGODkkzD3Fdz4I1LwBZOdP8JXuhwXc7fvLeKVFupXGeZFY+Yz8nl8nrXF+DtAg0PxHc+CfEF/q9vdHzLnQ9Qg1O4t/t1tkkxlVcRNNDnBUKPk2kKAM11+reBtRvLZbeTXoNYtV6W3iPSoL6MfTyxE3pySx4oA7yivJR4R1zTY40t9GIgVuU0PxNd2q4z/AA2zgRoPZXr0LwdBqFt4T0aDWt39pxWcUdzumMzGQIAxL/xHI5Pc0AbFFFFABRRRQAU2R1jRnkYKijJZjgAU6uQ8V+C4dc1ldSVNJac262znUdNF5tVWZlMYLqEOXbJIbPy9McgE2r+JvCV/BNpl7eafqyS/JLYwx/bi/PRokDE/iK5VtObT4ZD4Ij8ZWEaROVj3R/ZQQCVHlXzZRc8Yi2fgOa6Sz8FzLDHFf+JNZniX/lhatFYxA+3kIj/m5rg9V8MaB438aQaHpNgLvR9Huxca5qk7G58ydOUsUllLljkhpQv3VAUkFsUAczb6hJapY2l3afCOSSO1jT7HEWjurWRhvkjCwibCrJI/KkAkk8Zq5a2Fncwu0Fvp0DTfNKbPwxrMyybRgZdHTfgcAn1wK9+sbK1sLcQWNtBbQA5EcMYRQfoOKnoA8AeCCxuhdr5yvsVXkOn69pm5VyVUybnAVdzYByBk8DmpdL8mW/it9GvnkLzrc/Z9L8TQX83mA8M0d9EGLdxkk9CMYFe9VR1XSNN1iEQ6tp1nfRDolzAsq/kwNAHk1xE9vI019NYRXD7vNGqWlxpPmnJJ33CF43ySCwQDfgAkqABa8PX1yIbqxvNIkvdAMafv7OSC/gMu4ttSC3VSqZwx3Kd3QjqT248E6Vbpt0mTUNJwcqtheSRxrxjiLJj/APHaytQ8APdXP2iXVYr2fGDJqWl20rn/AIHGkbfkaAMv4VCVPGPieKSK7jjis7GOJrqFoXlQSXQD+WURYwTnCooUf72416fXC+DNNudL8deIILu6juXOmaeysiyqFXzbwbQJJZCOh6EDnp1J7qgCO5giuYHhuI1kicYZGGQR71JRRQAV4P8AErxhd3Evi6Gbw/49Fkuj3elxRJpKix3tvD3TSB8yAhUCkgBV3HB3nHvFc/8AEKyutS8A+JrHTozLfXOmXMMEYIBeRomCjnjkkdaAPOfC3xTGleCNGSXwT45uI7XTrdXuIdJHltiJcsCXHy8Zz0xXrum3tvqenWt/YyrNaXUSTwyL0dGAKkfUEGuC8MwyeI9MHhjVvD8sfh/SrW2tbie5lKfarqMIWiSMD95Cu3DOTtc5UBlBNejUAFFFFABRRRQBzXhP/kPeNP8AsLR/+kFpXS1zXhP/AJD3jT/sLR/+kFpXS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAMmjSaJ4pBlHUqw9QetQ6dYWmmWcdpp1rBaWsYwkUKBFX6AcVZooAKKKKACiiigAooooAxfF/hnTvFmjNp2qLKFDrNBcQP5c9rMvKTROOUkU8gj3ByCQeP/wCEo8ReBVePx5bS6toqElfEWm2+4xoFLH7VbplkxtbMiApyuQpr0qigCrpeo2WrWEN9pd3b3tlMCY57eQSI4BwcMODyCPwqrqniHR9Jure21XU7OymuBmFbmVY/N5xhS2ATyOBzXM6l8MdDk1KTVNAkvvDWrSsry3OjTeQJipJAliIMUgyxJ3ISfWs29g+IOmWMlnqenaF490xlRGUhbC6ky3zF433QOAMcApnFAHpYIKgg5B6EUteCXVz8OLGS4n17wf4p8HCA7WlS2u7WAkDqr2jmMgetVETwBqhafT/jX4msUP3Ym8SlFX/gMw3frQB7Rp/i/QNQ1280S31S3GsWkhjlsZSYpwQAchHAZlwQQygqQQQa3d3AODzXw5458K2nibxS7z/E3T5tHswII73W9XjuriQZJZoo4i3y+gYqT1Pt698Lde8K+FIms/DviHxh8QNXVFge3tUmkt4QT95EciGNeB8zOxGDg8kUAfQ1Y3ifxPovhe0S517UYLNJG2RK2WkmbIG2ONcs7cjhQTXHlfiP4m2iVtM8F2JI3LERqN/w3K7iBDHuXvhyK3vCvgPRfDtz9viin1DWSoR9V1OY3N24xjHmN90Y42ptX2oAwQnin4g7RcxXvhHwqWDNEX2apfLtzhipItkJOCATIdhHyBq7rQdH0/w/o9rpWi2kVnp9qmyGCIYVR1PuSSSSTySSTkmr9FABRRRQAUUUUAFFFFAHNWH/ACUnXf8AsE6f/wCjr2ulrmrD/kpOu/8AYJ0//wBHXtdLQAUUfSm4bHG3dQA7NeZfE7UIPEvhPxTaWVzerp+hxyTakYV2Q6iI4pWeyEwIIG5UEpTkDKZBLbe91mz/ALS0i+sHYxC6gkgL9doZSucd8Z6V4L43+D1honhiHS9D1i+uL69xpOn219ZWk+WkJZz5gg3oqr5kjOpDAKxBzgEA930O/FxoGm3VzJCrTWsUrMuFXLKDwM8DmtFJEfdsZW2nacHOD6V84fDv4YPqUV7pPiLVLK21nRpltbqC00LTc+URuhljlaFnIdMEOQGDKwIypNe8eEvDWm+FNHXTNGjlS3EjysZZWleSRjlnZmJJJPNAGzRRRQAUUUUAc14T/wCQ940/7C0f/pBaV0tc14T/AOQ940/7C0f/AKQWldLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAx1JI2nFUdQ0ex1PH9pWNld46faIFkx+YrRooAoWujaXaIFtdNsoVByBHAqjPrwKvKoVdoACjjAFLRQAUUUUAFFFFABRRRQAUUUUAFFFFAGFqfh5rvVZtRstX1HTLqaGK3ka1WBg6RtIyjEsbgcyv0x2qv8A8I5qn/Q6eIP+/Nh/8jV0tFAHNf8ACOap/wBDp4g/782H/wAjUf8ACOap/wBDp4g/782H/wAjV0tFAHNHw3qhHPjPxB/35sP/AJGqCXwfdS3MNxL4r1l7iAMIpWtdPLRhhhtp+zZGQBnHWusooA5IeD7oXrXg8V6yLxoxC0/2XT/MKAkhS32bO0EkgdMk1Y/4RzVP+h08Qf8Afmw/+Rq6WigDmv8AhHNU/wCh08Qf9+bD/wCRqP8AhHNU/wCh08Qf9+bD/wCRq6WigDmv+Ec1T/odPEH/AH5sP/kaj/hHNU/6HTxB/wB+bD/5GrpaKAMjw7og0Vb9mv7y/uL24+0zz3QjDMwjSMDEaIoAWNe3rWvRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Smead-Jones closure. Far-far-near-near. Suture passes laterally through rectus sheath and peritoneum and adjacent fat. The suture crosses midline to pick up medial edge of fascia on opposite side of incision. (B) Alternative closure. Far-near-near-far. The far bite is 1 to 1.5 cm away from the edge. The near bite is 5 mm from the edge. (C) Running mass closure. Two sutures are used, beginning from each pole of the incision. Sutures are 1 cm away from edge and 1 cm apart. The sutures are tied at the midpoint of the incision.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Therese Trenhaile, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_6_18533=[""].join("\n");
var outline_f18_6_18533=null;
var title_f18_6_18534="Scrub typhus: Clinical features and diagnosis";
var content_f18_6_18534=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Scrub typhus: Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/6/18534/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/6/18534/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/6/18534/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/6/18534/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/6/18534/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/6/18534/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/6/18534/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scrub typhus is a mite-borne infectious disease caused by Orientia tsutsugamushi (previously called Rickettsia tsutsugamushi). This disease was first described by the Chinese in the third century, but the first description of its classic features did not appear in the western literature until the end of the nineteenth century. Knowledge about scrub typhus increased dramatically during World War II due to its common occurrence in soldiers fighting on both sides in the Pacific theater.",
"   </p>",
"   <p>",
"    The epidemiology, clinical features, and diagnosis of scrub typhus will be reviewed here. Treatment of this disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26852?source=see_link\">",
"     \"Scrub typhus: Treatment and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;O. tsutsugamushi is a gram-negative coccobacillus that is antigenically distinct from the typhus group rickettsiae. This organism has features that are common to and distinct from other rickettsiae.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Like all rickettsiae, it cannot be propagated in cell-free media. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31364?source=see_link\">",
"       \"Biology of Rickettsia rickettsii infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Similar to typhus group rickettsiae, O. tsutsugamushi has a slime layer that may play a role in both pathogenicity and virulence.",
"     </li>",
"     <li>",
"      Unlike other rickettsiae, the trilaminar outer membrane of O. tsutsugamushi is unique in its morphology.",
"     </li>",
"     <li>",
"      O. tsutsugamushi is unique in that it is released from infected cells by budding from the plasma membrane of host cells. It may then be phagocytosed by adjacent cells while still coated with its original host cell membranes. Rickettsial phospholipase A2 appears to be involved as a mediator of entry into host cells with subsequent release from phagosomes and injury to the host cell [",
"      <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Organisms disseminate widely after initial inoculation into the skin. One study showed that O. tsutsugamushi could be detected by staining mononuclear cells in the peripheral blood of three of seven patients studied with acute scrub typhus [",
"      <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are three variants or strains of O. tsutsugamushi (Karp, Gilliam, and Kato). Infection with one strain does not preclude reinfection with a different strain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;O. tsutsugamushi is distributed throughout the Asia Pacific rim. Scrub typhus is endemic in Korea, China, Taiwan, Japan, Pakistan, India, Thailand, Malaysia, and in the tropical (northern) regions of Australia. A study described the presence of scrub typhus in a national park in the Northern Territory of Australia, an area frequently visited by tourists that was not previously known to be endemic for O. tsutsugamushi [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/3\">",
"     3",
"    </a>",
"    ]. Although most cases of scrub typhus occur in rural areas, a number of cases have been acquired in settings such as suburban Bangkok, where seroprevalence exceeds 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/4\">",
"     4",
"    </a>",
"    ]. Focal or discrete geographic clustering of cases is a well known phenomenon, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Vectors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reservoir and vector of scrub typhus are larval trombiculid mites of the genus Leptotrombidium. These larval mites (also known as chiggers) maintain the infection in successive generations via transovarial transmission. At least 8 of the known 60 species of trombiculid mites are capable of transmitting scrub typhus. The disease typically occurs 7 to 10 days after the bite of an infected chigger (range 6 to 19 days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ecology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scrub typhus is characteristically a geographically focal disease. Transmission of O. tsutsugamushi may occur in sharply delineated \"mite islands\" that consist of focal locations of scrub vegetation as small as a few square meters. Mites live on the vegetation, and moisture and temperature conditions are ideal for propagation of chiggers and their small rodent hosts. The risk of disease transmission from chigger bites may be extremely high when humans enter these mite islands. As an example, a classic study performed over 50 years ago found that nearly all Australian soldiers on training exercises in Queensland who camped in a small geographic area developed scrub typhus. In contrast, no soldiers who camped in nearby areas developed the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Imported disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ease of air travel and relatively long incubation period of scrub typhus (up to two weeks) allow the disease to occur in tourists returning to regions where it is not endemic, and where physicians are not familiar with its clinical and epidemiologic features. Cases of scrub typhus have been described in tourists returning to the United States, Canada, and Europe from endemic regions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/6-9\">",
"     6-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INCUBATION PERIOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection commonly presents as an acute febrile illness 7 to 10 days after the bite of an infected larval trombiculid mite (chigger) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scrub typhus may begin insidiously with headache, anorexia, and malaise, or start abruptly with chills and fever. As the illness evolves, most patients develop the following symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High fever",
"     </li>",
"     <li>",
"      Intense generalized headache",
"     </li>",
"     <li>",
"      Diffuse myalgias",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rash, eschar, and other signs and symptoms may also be present. The severity of infection can range from mild symptoms and signs to multiorgan failure; about 4 percent of patients requiring hospitalization have fatal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/11\">",
"     11",
"    </a>",
"    ]. One study of 155 patients found a relationship between the level of rickettsial DNA in blood samples at the time of admission and risk of mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-half of all patients develop a characteristically nonpruritic, macular or maculopapular rash. The rash typically begins on the abdomen and spreads to the extremities. The face is also often involved. Rarely, petechiae may develop.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Eschar",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients develop a localized necrotic skin lesion (eschar) at the site of their infecting chigger bite (",
"    <a class=\"graphic graphic_picture graphicRef70635 \" href=\"UTD.htm?14/60/15296\">",
"     picture 1",
"    </a>",
"    ). The eschar may develop before the onset of systemic symptoms, and can occur in multiple locations. The frequency of eschar in patients with scrub typhus is highly variable. As an example, it developed in 36 of 74 (46 percent) American servicemen in South Vietnam [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/12\">",
"     12",
"    </a>",
"    ], while another study found a higher incidence of 60 to 88 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other signs and symptoms may also be seen in scrub typhus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Generalized lymphadenopathy occurs in the majority of patients, and may be accompanied by inflammation of the lymphatic sinuses, splenomegaly, and portal triaditis.",
"     </li>",
"     <li>",
"      Nausea, vomiting,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diarrhea are prominent findings in approximately one-fourth of patients. Endoscopy was performed in 58 patients with scrub typhus and prominent gastrointestinal symptoms selected from 256 patients with scrub typhus seen at a single Korean center over a five-year period. All patients had one or more endoscopic abnormalities, and 33 of 56 patients had changes consisting of superficial ulcers, erosions, or actively bleeding ulcers. Moreover, the presence of endoscopic lesions in the upper gastrointestinal tract was correlated with the occurrence of cutaneous lesions and severity of illness [",
"      <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Respiratory complaints are often present; cough occurred in 45 percent of patients in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/12\">",
"       12",
"      </a>",
"      ]. Rarely, acute respiratory distress syndrome may occur. In one case series, pulmonary complaints were present in 62 percent of 130 Thai patients with scrub typhus. Sixty-five percent of these 130 patients had radiographic abnormalities at presentation. The most common abnormalities were bilateral reticular opacities (49 percent), cardiomegaly (29 percent), and congestive heart failure (19 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Relative bradycardia occurs commonly in patients with scrub typhus [",
"      <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/16-18\">",
"       16-18",
"      </a>",
"      ]. Relative bradycardia has been defined as a median increase in heart rate &lt;10",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      per 1&ordm;C increase in temperature [",
"      <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Involvement of blood vessels in the central nervous system may produce meningitis, with a predominant mononuclear cell response. Meningitis and encephalitis syndromes occurred in 9 of 72 patients in a report from Thailand [",
"      <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/19\">",
"       19",
"      </a>",
"      ]. Acute hearing loss or tinnitus occurred in six patients who presented with scrub typhus after being ill for more than one week [",
"      <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/20\">",
"       20",
"      </a>",
"      ]. Only two of the six patients had concurrent symptoms of encephalitis.",
"     </li>",
"     <li>",
"      While pericardial effusion has been reported in autopsy series, clinical pericarditis is not common. However, a clinical case has been published from Korea of pericarditis in which the organism was demonstrated by indirect immunofluorescence of pericardial fluid [",
"      <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with all rickettsial diseases, no laboratory test is diagnostically reliable in the early phases of scrub typhus. The disease is usually recognized when clinicians correlate the presence of compatible clinical signs, symptoms, and laboratory features, with epidemiologic clues (eg, recent exposure to environments in which chiggers are known or suspected to be present).",
"   </p>",
"   <p>",
"    Patients with scrub typhus may develop the following laboratory abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with severe illness develop thrombocytopenia.",
"     </li>",
"     <li>",
"      Elevations in hepatic enzymes, bilirubin, and creatinine.",
"     </li>",
"     <li>",
"      Leukopenia or leukocytosis can occur, but most have a normal white blood cell count.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these laboratory findings are relatively nonspecific, four methods can be used to more definitively confirm the presence of O. tsutsugamushi infection: serology, biopsy, culture, and polymerase chain reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indirect fluorescent antibody (IFA) test remains the mainstay of serologic diagnosis. This test is available in most state health laboratories, which send the specimens to the Centers for Disease Control in Atlanta, GA. A battery of antigens from common strains of O. tsutsugamushi should be used to detect convalescent antibodies because of the organism's antigenic heterogeneity.",
"   </p>",
"   <p>",
"    Among patients living in endemic areas, the serologic diagnosis of acute infection must be differentiated from background immunity against scrub typhus. A 2007 review made the following recommendations for diagnosis using the IFA assay [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A conclusive diagnosis of acute scrub typhus infection using the IFA assay should be based upon at least a fourfold increase in titer in paired samples drawn at least 14 days apart.",
"     </li>",
"     <li>",
"      A single measurement may be informative when there are locally validated criteria for a positive test. When a single measurement is performed, the most common cutoff titer is 1:50 (range 1:10 to 1:400).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A single measurement may also be used to make a preliminary diagnosis in travelers who live in areas in which scrub typhus is not endemic and who have recently returned from an endemic area [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/22\">",
"     22",
"    </a>",
"    ]. However, only paired titers can make a definitive diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An enzyme-linked immunosorbent assay and a passive hemagglutination assay have also been developed for the diagnosis of scrub typhus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], and a dot blot immunoassay dipstick, which is undergoing clinical evaluation, may permit rapid diagnosis of scrub typhus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/26\">",
"     26",
"    </a>",
"    ]. The Weil Felix test, based upon a fortuitously discovered cross reaction between anti-rickettsial antibodies and Proteus antigens (OX2 and OX19), is neither specific nor sensitive. Thus, its use is no longer advised.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Biopsy of an eschar or generalized rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathological hallmark of scrub typhus is a lymphohistiocytic vasculitis. Damage to endothelial cells occurs early in infection, leading to widespread vascular dysfunction. This endothelial injury causes a loss of vascular integrity, egress of plasma and plasma proteins, and microscopic and macroscopic hemorrhages. Thus, the histologic changes in biopsies of eschars include focal areas of cutaneous necrosis surrounded by a zone of intense vasculitis, with perivascular collections of lymphocytes and macrophages. Thrombosis of small blood vessels can also occur. Demonstration of these typical vasculitic changes can be diagnostic, even when rickettsiae are not demonstrable by fluorescent antibody conjugates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Culture of this organism is available in only a few centers. Specialized laboratory facilities with rigorous quality control and laboratory safety measures are required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCR technology applied to the blood of patients with scrub typhus can definitively establish the diagnosis, even in the minority of patients who lack IgM antibodies early in the course of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. The sensitivity of a nested PCR assay using buffy coat preparations was 82 percent and the specificity was 100 percent in a study of 135 Korean patients with possible scrub typhus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition to serum PCR, eschar PCR also appears to be a sensitive and specific assay for scrub typhus despite prior antibiotic treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/30\">",
"     30",
"    </a>",
"    ]. However, these tests are only available in specialized centers that have access to the required primers and laboratory facilities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scrub typhus may be confused with a number of different infectious illnesses.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malaria and dengue share some common clinical features and similar endemic patterns with scrub typhus.",
"     </li>",
"     <li>",
"      Leptospirosis is a common disease in some tropical regions where scrub typhus also occurs. Rarely, coinfection with scrub typhus and leptospirosis may occur. In one study of 296 febrile Thai patients, 69 patients (23 percent) had leptospirosis; 57 patients (19 percent) had scrub typhus and 11 patients (4 percent) had evidence of coinfection with leptospira and O. tsutsugamushi [",
"      <a class=\"abstract\" href=\"UTD.htm?18/6/18534/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other rickettsial diseases, such as infections with the spotted fever group of rickettsiae (eg, R. australis, R. japonica, and R. sibirica), may mimic scrub typhus. Infection with R. australis and R. sibirica may even be associated with a localized eschar at the site of the infecting tick bite. These diseases can be almost identical, particularly when there is no history of tick bite. Fortunately the treatment for these other rickettsial diseases is identical to that for scrub typhus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28808?source=see_link\">",
"       \"Other spotted fever group rickettsial infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Scrub typhus may mimic infection with Salmonella typhi in areas of the tropics where typhoid fever is common. This confusion is particularly true in patients who lack a rash or localized eschar, and in whom gastrointestinal symptoms are prominent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1037559\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Scrub typhus is a mite-borne infectious disease caused by Orientia tsutsugamushi (previously called Rickettsia tsutsugamushi). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Like all rickettsiae, this rickettsia cannot be propagated in cell-free media. Similar to the typhus group of rickettsiae, O. tsutsugamushi has a slime layer that may play a role in both pathogenicity and virulence. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Scrub typhus is endemic in Korea, China, Taiwan, Japan, Pakistan, India, Thailand, Malaysia, and Australia. The reservoir and vector of scrub typhus are larval trombiculid mites of the genus Leptotrombidium. Imported disease has been described in tourists returning from endemic areas. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Scrub typhus may begin insidiously with headache, anorexia, and malaise, or start abruptly with chills and fever. As the illness evolves, most patients develop high fever, worsening of headache severity, and myalgias. An eschar or rash may develop in a subset of patients. The severity of infection can range from mild symptoms and signs to multiorgan failure. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic methods for confirmation of O. tsutsugamushi infection include serology, biopsy, culture, and polymerase chain reaction. The indirect fluorescent antibody (IFA) test remains the mainstay of serologic diagnosis; a four-fold rise in titers over a 14-day period is conclusive. Culture and polymerase chain reaction (PCR) testing is only available in specialized research facilities. The pathological hallmark of scrub typhus on skin biopsy is a lymphohistiocytic vasculitis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of scrub typhus includes malaria, dengue, leptospirosis, and other rickettsial diseases. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/1\">",
"      Walker DH, Feng HM, Popov VL. Rickettsial phospholipase A2 as a pathogenic mechanism in a model of cell injury by typhus and spotted fever group rickettsiae. Am J Trop Med Hyg 2001; 65:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/2\">",
"      Walsh DS, Myint KS, Kantipong P, et al. Orientia tsutsugamushi in peripheral white blood cells of patients with acute scrub typhus. Am J Trop Med Hyg 2001; 65:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/3\">",
"      Currie B, O'Connor L, Dwyer B. A new focus of scrub typhus in tropical Australia. Am J Trop Med Hyg 1993; 49:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/4\">",
"      Strickman D, Tanskul P, Eamsila C, Kelly DJ. Prevalence of antibodies to rickettsiae in the human population of suburban Bangkok. Am J Trop Med Hyg 1994; 51:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/5\">",
"      LANG WR. A case of Addison's suprarenal syndrome of primary pituitary origin. Med J Aust 1946; 1:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/6\">",
"      Watt G, Strickman D. Life-threatening scrub typhus in a traveler returning from Thailand. Clin Infect Dis 1994; 18:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/7\">",
"      Dupon M, Rogues AM, Malou M, et al. Scrub typhus: an imported Rickettsial disease. Infection 1992; 20:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/8\">",
"      Marschang A, Nothdurft HD, Kumlien S, von Sonnenburg F. Imported rickettsioses in German travelers. Infection 1995; 23:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/9\">",
"      McDonald JC, MacLean JD, McDade JE. Imported rickettsial disease: clinical and epidemiologic features. Am J Med 1988; 85:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/10\">",
"      Sonthayanon P, Chierakul W, Wuthiekanun V, et al. Association of high Orientia tsutsugamushi DNA loads with disease of greater severity in adults with scrub typhus. J Clin Microbiol 2009; 47:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/11\">",
"      Sonthayanon P, Chierakul W, Wuthiekanun V, et al. Rapid diagnosis of scrub typhus in rural Thailand using polymerase chain reaction. Am J Trop Med Hyg 2006; 75:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/12\">",
"      Berman SJ, Kundin WD. Scrub typhus in South Vietnam. A study of 87 cases. Ann Intern Med 1973; 79:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/13\">",
"      Sheehy TW, Hazlett D, Turk RE. Scrub typhus. A comparison of chloramphenicol and tetracycline in its treatment. Arch Intern Med 1973; 132:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/14\">",
"      Kim SJ, Chung IK, Chung IS, et al. The clinical significance of upper gastrointestinal endoscopy in gastrointestinal vasculitis related to scrub typhus. Endoscopy 2000; 32:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/15\">",
"      Charoensak A, Chawalparit O, Suttinont C, et al. Scrub typhus: chest radiographic and clinical findings in 130 Thai patients. J Med Assoc Thai 2006; 89:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/16\">",
"      Aronoff DM, Watt G. Prevalence of relative bradycardia in Orientia tsutsugamushi infection. Am J Trop Med Hyg 2003; 68:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/17\">",
"      Hazlett DR. Scrub typhus in Vietnam: experience at the 8th Field Hospital. Mil Med 1970; 135:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/18\">",
"      Machella TE, Forrester JS. Mite or scrub typhus: a clinical and laboratory study of 64 cases. Am J Med Sci 1945; 38:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/19\">",
"      Silpapojakul K, Ukkachoke C, Krisanapan S, Silpapojakul K. Rickettsial meningitis and encephalitis. Arch Intern Med 1991; 151:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/20\">",
"      Premaratna R, Chandrasena TG, Dassayake AS, et al. Acute hearing loss due to scrub typhus: a forgotten complication of a reemerging disease. Clin Infect Dis 2006; 42:e6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/21\">",
"      Chang JH, Ju MS, Chang JE, et al. Pericarditis due to Tsutsugamushi disease. Scand J Infect Dis 2000; 32:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/22\">",
"      Blacksell SD, Bryant NJ, Paris DH, et al. Scrub typhus serologic testing with the indirect immunofluorescence method as a diagnostic gold standard: a lack of consensus leads to a lot of confusion. Clin Infect Dis 2007; 44:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/23\">",
"      Jensenius M, Fournier PE, Raoult D. Rickettsioses and the international traveler. Clin Infect Dis 2004; 39:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/24\">",
"      Kim IS, Seong SY, Woo SG, et al. High-level expression of a 56-kilodalton protein gene (bor56) of Rickettsia tsutsugamushi Boryong and its application to enzyme-linked immunosorbent assays. J Clin Microbiol 1993; 31:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/25\">",
"      Kim IS, Seong SY, Woo SG, et al. Rapid diagnosis of scrub typhus by a passive hemagglutination assay using recombinant 56-kilodalton polypeptides. J Clin Microbiol 1993; 31:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/26\">",
"      Watt G, Strickman D, Kantipong P, et al. Performance of a dot blot immunoassay for the rapid diagnosis of scrub typhus in a longitudinal case series. J Infect Dis 1998; 177:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/27\">",
"      Sugita Y, Yamakawa Y, Takahashi K, et al. A polymerase chain reaction system for rapid diagnosis of scrub typhus within six hours. Am J Trop Med Hyg 1993; 49:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/28\">",
"      Murai K, Okayama A, Horinouchi H, et al. Eradication of Rickettsia tsutsugamushi from patients' blood by chemotherapy, as assessed by the polymerase chain reaction. Am J Trop Med Hyg 1995; 52:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/29\">",
"      Kim DM, Yun NR, Yang TY, et al. Usefulness of nested PCR for the diagnosis of scrub typhus in clinical practice: A prospective study. Am J Trop Med Hyg 2006; 75:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/30\">",
"      Kim DM, Kim HL, Park CY, et al. Clinical usefulness of eschar polymerase chain reaction for the diagnosis of scrub typhus: a prospective study. Clin Infect Dis 2006; 43:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18534/abstract/31\">",
"      Phimda K, Hoontrakul S, Suttinont C, et al. Doxycycline versus azithromycin for treatment of leptospirosis and scrub typhus. Antimicrob Agents Chemother 2007; 51:3259.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7910 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.65.66-4367187BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_6_18534=[""].join("\n");
var outline_f18_6_18534=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1037559\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Vectors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ecology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Imported disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INCUBATION PERIOD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Eschar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Biopsy of an eschar or generalized rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1037559\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7910\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7910|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/60/15296\" title=\"picture 1\">",
"      Eschar in scrub typhus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31364?source=related_link\">",
"      Biology of Rickettsia rickettsii infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28808?source=related_link\">",
"      Other spotted fever group rickettsial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26852?source=related_link\">",
"      Scrub typhus: Treatment and prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_6_18535="Surgical drainage of dorsal subcutaneous abscess of the hand";
var content_f18_6_18535=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F53109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F53109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Surgical drainage of dorsal subcutaneous abscess of the hand",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 584px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The dorsal skin of the hand is loosely anchored to the underlying tissue, which allows the spread of infection into two potential spaces; the dorsal subcutaneous space, which is superficial to the extensor tendons, and the dorsal subaponeurotic space, which is deep to the extensor tendons.",
"    <br>",
"     Panels A through C demonstrate surgical drainage of a subcutaneous abscess of the dorsum of the right hand:",
"     <br>",
"      (A) Pre-operative appearance.",
"      <br>",
"       (B) Intra-operative appearance.",
"       <br>",
"        (C) Post-operative appearance.",
"        <br>",
"         Panel D shows a more extensive dorsal subaponeurotic abscess. Patients who require extensive debridement may need additional surgical procedures to resurface the resulting soft tissue defect.",
"         <div class=\"footnotes\">",
"         </div>",
"         <div class=\"reference\">",
"         </div>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_6_18535=[""].join("\n");
var outline_f18_6_18535=null;
var title_f18_6_18536="Central hypothyroidism";
var content_f18_6_18536=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Central hypothyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/6/18536/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/6/18536/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/6/18536/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/6/18536/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/6/18536/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/6/18536/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/6/18536/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overwhelming majority of patients who have hypothyroidism have thyroid disease (primary hypothyroidism). Central hypothyroidism refers to thyroid hormone deficiency due to a disorder of the pituitary, hypothalamus, or hypothalamic-pituitary portal circulation. Pituitary thyrotropin (TSH) production is regulated in part by thyrotropin-releasing hormone (TRH), which is secreted from the paraventricular nucleus in the hypothalamus. TRH is released into portal blood vessels and transported to the anterior pituitary gland where it regulates the synthesis, glycosylation, and release of TSH (",
"    <a class=\"graphic graphic_figure graphicRef75399 \" href=\"UTD.htm?10/24/10629\">",
"     figure 1",
"    </a>",
"    ). TSH stimulates the synthesis and secretion of triiodothyronine (T3) and thyroxine (T4). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=see_link\">",
"     \"Thyroid hormone synthesis and physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypothalamic-pituitary tumors can cause central hypothyroidism by compression of the hypothalamus or pituitary, which results in a decrease in TRH or TSH secretion, or by disrupting signalling between the hypothalamus and pituitary. Other causes of central hypothyroidism include lymphocytic hypophysitis, Sheehan syndrome, traumatic brain injury, subarachnoid hemorrhage, and infiltrative disorders. Patients with central hypothyroidism frequently have other pituitary hormone deficiencies.",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and treatment of central hypothyroidism will be reviewed here. The approach to patients with primary, subclinical, and congenital hypothyroidism is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=see_link\">",
"     \"Subclinical hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=see_link\">",
"     \"Clinical features and detection of congenital hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/46/15081?source=see_link\">",
"     \"Treatment and prognosis of congenital hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central hypothyroidism is a rare cause of hypothyroidism, estimated to occur in 1:20,000 to 1:80,000 in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/1\">",
"     1",
"    </a>",
"    ]. The causes of central hypothyroidism are the same as the causes of hypopituitarism (",
"    <a class=\"graphic graphic_table graphicRef55951 \" href=\"UTD.htm?18/8/18571\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=see_link\">",
"     \"Causes of hypopituitarism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pituitary mass lesions, especially pituitary adenomas, are the most common cause of central hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/4\">",
"     4",
"    </a>",
"    ]. Pituitary tumors can cause hypothyroidism by compression of pituitary thyrotrophs, interruption of the hypothalamic-pituitary portal blood flow, or rarely by acute hemorrhage or infarction resulting in pituitary apoplexy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Other mass lesions that can cause central hypothyroidism include cysts and abscesses, meningiomas and dysgerminomas, metastatic tumors, and craniopharyngiomas, which may enter the sella or remain suprasellar.",
"   </p>",
"   <p>",
"    In addition, surgery or radiation therapy for pituitary adenomas or other mass lesions can cause central hypothyroidism. Radiation in high doses (&ge;40 Gray) to the brain, orbits, infratemporal, nasopharyngeal, or oropharyngeal regions can affect the pituitary gland or hypothalamus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H38#H38\">",
"     \"Complications of cranial irradiation\", section on 'Endocrinopathies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infiltrative disorders affecting the pituitary or the hypothalamus include hemochromatosis, tuberculosis, syphilis, sarcoidosis, fungal infections, toxoplasmosis, and histiocytosis. Autoimmune lymphocytic hypophysitis is a rare cause of transient or permanent pituitary dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/7\">",
"     7",
"    </a>",
"    ]. Other causes include head trauma with injury of the stalk [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/8\">",
"     8",
"    </a>",
"    ], pituitary apoplexy, and Sheehan's syndrome (postpartum pituitary necrosis).",
"   </p>",
"   <p>",
"    Developmental abnormalities, internal carotid aneurysms, and other CNS tumors may also damage the hypothalamus.",
"   </p>",
"   <p>",
"    Several rare genetic defects have also been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A point mutation in the gene that controls the transcription factor pit-1 may result in multiple pituitary hormone deficiencies [",
"      <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=see_link\">",
"       \"Causes of hypopituitarism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An inactivating mutation in the TRH-receptor gene was found to cause central hypothyroidism in one patient [",
"      <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mutations in the gene coding for the TSH-beta subunit result in isolated central hypothyroidism at birth [",
"      <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/11-15\">",
"       11-15",
"      </a>",
"      ]. In several Japanese families, a single nucleotide substitution resulted in an altered TSH-beta subunit unable to bind to the alpha-subunit to form intact TSH [",
"      <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/11\">",
"       11",
"      </a>",
"      ]. In two Greek families and in an Egyptian girl, single nucleotide substitutions resulted in a severely truncated TSH-beta subunit [",
"      <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/12,14\">",
"       12,14",
"      </a>",
"      ]. Serum alpha-subunit concentrations may be high, and some mutated forms of TSH-beta are detected in some TSH assays [",
"      <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Idiopathic isolated TSH or TRH deficiency is another rare cause of central hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. One cause of the former is treatment (of patients with lymphoma) with a retinoid X receptor ligand (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/10/31904?source=see_link\">",
"     bexarotene",
"    </a>",
"    ) that selectively inhibits TSH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Growth hormone replacement therapy in growth hormone deficient adults may unmask central hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In one study of 84 patients with growth hormone deficiency, all of whom were initiating growth hormone therapy, 30 (36 percent) subsequently required T4 therapy because of reduced serum T4 concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18020064\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18020398\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of central hypothyroidism are similar to but sometimes milder than those of primary hypothyroidism. Common symptoms of central hypothyroidism include fatigue, cold intolerance, muscle cramps, headache, and weight gain (",
"    <a class=\"graphic graphic_table graphicRef62676 \" href=\"UTD.htm?41/41/42651\">",
"     table 2",
"    </a>",
"    ). Goiter is not a typical finding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with central hypothyroidism have a history of previous hypothalamic or pituitary disease, cranial irradiation, infiltrating disease, or trauma, with accompanying symptoms of deficiency or excess of other pituitary hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/1\">",
"     1",
"    </a>",
"    ]. In patients with coexisting pituitary hormone abnormalities, the symptoms of hypothyroidism may be less obvious. As an example, hot flashes due to hypogonadism may mask the cold intolerance of hypothyroidism. The coexistence of hypothyroidism and adrenal insufficiency may result in anorexia and weight loss, while hypothyroid acromegalic patients may complain of sweating. Children may present with growth retardation and delayed sexual maturation, precocious puberty, or dwarfism and cretinism. The presence of polyuria and polydipsia suggests diabetes insipidus and posterior pituitary or hypothalamic involvement (eg, due to a craniopharyngioma).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18020102\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18020410\">",
"    <span class=\"h3\">",
"     Thyroid function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with central hypothyroidism, serum free T4 is low or low-normal, but serum TSH may be low, normal, or even slightly elevated (up to about 10",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef67935 \" href=\"UTD.htm?26/20/26956\">",
"     table 3",
"    </a>",
"    ). In a retrospective study of 108 adult patients with central hypothyroidism (childhood onset n = 26, adult onset n = 82), initial free T4 results were in the low-normal range in only 18 percent of patients with adult onset (the remainder having levels below normal), compared with 65 percent of patients with childhood onset central hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/21\">",
"     21",
"    </a>",
"    ]. In 51 patients, TSH was measured with a sensitive immunoradiometric assay, and the following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      8 percent of patients had low (&lt;0.2",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"      serum TSH concentrations",
"     </li>",
"     <li>",
"      84 percent had normal values",
"     </li>",
"     <li>",
"      8 percent had high (&gt;3.5",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"      values",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Normal or high serum TSH concentrations in some patients with central hypothyroidism is due, in part, to the secretion of TSH that has reduced biologic activity but normal immunoactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Reduced bioactivity is due to abnormalities in glycosylation of the TSH subunits, which is under the control of TRH [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/22,24\">",
"     22,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a diurnal rhythm in TSH secretion, with a surge late in the evening. This appears to be under hypothalamic control, and is absent in many patients with central hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Thus, TSH measurements may be normal during the daytime, but the absence of a nocturnal rise in TSH reduces the overall quantity of TSH secreted by the pituitary gland, causing clinical hypothyroidism.",
"   </p>",
"   <p>",
"    In patients with central hypothyroidism, serum total and free triiodothyronine (T3) levels may be normal or low [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/21,27\">",
"     21,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18020236\">",
"    <span class=\"h3\">",
"     TRH stimulation test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although TRH is not currently available in the United States, it is widely available in other countries. A thyrotropin releasing hormone (TRH) stimulation test involves the intravenous administration of TRH (200 mcg) with measurement of serum TSH at baseline and then 20 and 60 minutes after TRH administration. The normal increment in TSH at 20 minutes is 5 to 30",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    with a subsequent decrease at 60 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/28\">",
"     28",
"    </a>",
"    ]. Classically, one would expect no serum TSH response to TRH in patients with pituitary disease and a delayed response in patients with hypothalamic disease (",
"    <a class=\"graphic graphic_figure graphicRef75399 \" href=\"UTD.htm?10/24/10629\">",
"     figure 1",
"    </a>",
"    ). In fact, the response to TRH is highly variable in these circumstances, limiting the utility of this test in distinguishing between pituitary and hypothalamic disease as a cause of central hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A TRH stimulation test may be useful in distinguishing non-thyroidal illness from central hypothyroidism due to pituitary disease. Patients with nonthyroidal illness have a blunted nocturnal rise in serum TSH concentrations, but usually have a normal serum TSH response to TRH. (See",
"    <a class=\"local\" href=\"#H977108\">",
"     'Transient central hypothyroidism'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=see_link&amp;anchor=H9#H9\">",
"     \"Thyroid function in nonthyroidal illness\", section on 'Transient central hypothyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TRH stimulation tests (and measurement of nocturnal TSH) have been performed in childhood cancer survivors who have received cranial irradiation to detect subtle central hypothyroidism. This topic is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39223?source=see_link&amp;anchor=H7#H7\">",
"     \"Growth failure after childhood cancer: Role of hypothyroidism\", section on 'Central hypothyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H977219\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with pituitary tumors, there may be laboratory evidence of deficiency or excess of other pituitary hormones, such as hypogonadism or hyperprolactinemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=see_link\">",
"     \"Causes, presentation, and evaluation of sellar masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22447146\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of central hypothyroidism is based upon clinical manifestations and thyroid function tests. The majority of patients with central hypothyroidism have coexisting deficiencies in other pituitary hormones, although isolated TSH deficiency may also occur. Central hypothyroidism should be suspected in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      There is known hypothalamic or pituitary disease",
"     </li>",
"     <li>",
"      A mass lesion is present in the pituitary",
"     </li>",
"     <li>",
"      When symptoms and signs of hypothyroidism are associated with other hormonal deficiencies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In hypothyroidism caused by hypothalamic or pituitary disease, TSH secretion does not increase appropriately as T4 secretion falls. Thus, we measure both serum TSH and free T4 if pituitary or hypothalamic disease is suspected. We also measure free T4 if the patient has convincing symptoms of hypothyroidism despite a normal TSH result. In patients with central hypothyroidism, the serum free T4 value is low-normal or low and serum TSH may be frankly low, inappropriately normal (for the low T4), or slightly high (5 to 10",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    due to secretion of biologically inactive TSH (",
"    <a class=\"graphic graphic_table graphicRef67935 \" href=\"UTD.htm?26/20/26956\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis of and screening for hypothyroidism\", section on 'Secondary and tertiary (central) hypothyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is not necessary to measure T3 in most patients with suspected central hypothyroidism. However, it may be helpful to measure T3 when the diagnosis of central hypothyroidism is uncertain. As an example, patients who are taking T3 supplements or who have autonomous thyroid nodules may have suppressed TSH and low free T4 levels, similar to that seen in patients with central hypothyroidism; however, serum T3 levels are usually elevated or high-normal, rather than normal or low. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'TSH low'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with a history of previous hypothalamic-pituitary disease, with accompanying symptoms of deficiency or excess of other pituitary hormones, and a low or low-normal free T4 with a low or inappropriately normal TSH, the diagnosis of central hypothyroidism is straightforward. However, for patients without previous",
"    <span class=\"nowrap\">",
"     hypothalamic/pituitary",
"    </span>",
"    disease, it may be difficult to distinguish mild central hypothyroidism from mild primary hypothyroidism or subclinical hyperthyroidism. Some drugs can affect thyroid hormone metabolism, mimicking the thyroid function test abnormalities seen in patients with central hypothyroidism. In addition, transient central hypothyroidism may occur in some settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     TSH slightly high",
"    </span>",
"   </p>",
"   <p>",
"    <strong>",
"     Central versus primary hypothyroidism",
"    </strong>",
"    &mdash; A patient with a low serum total or free T4 concentration (eg, free T4 0.7 to 0.9",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    [normal range 0.9 to 1.8",
"    <span class=\"nowrap\">",
"     ng/dL])",
"    </span>",
"    and a slightly high serum TSH concentration (eg, 5 to 10",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    [normal range 0.5 to 5.0",
"    <span class=\"nowrap\">",
"     mU/L])",
"    </span>",
"    could have either primary or central hypothyroidism. A higher serum TSH value would be expected if the patient had primary hypothyroidism, but since patients with central hypothyroidism may have elevations of biologically inactive TSH, definitive diagnosis requires further evaluation.",
"   </p>",
"   <p>",
"    In this setting, we measure anti-thyroid peroxidase (TPO) antibodies, gonadotropins, and estradiol or testosterone. A high serum TPO antibody concentration suggests chronic autoimmune (Hashimoto's) thyroiditis and primary hypothyroidism, whereas absence of anti-TPO antibodies and abnormalities in other pituitary hormones favors central hypothyroidism. As examples, amenorrhea in premenopausal women, the absence of high serum follicle-stimulating hormone concentrations in postmenopausal women, and low serum testosterone and normal or low luteinizing hormone concentrations in men suggest the presence of secondary hypogonadism. Hyperprolactinemia may be present in both central and primary hypothyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     TSH low",
"    </span>",
"   </p>",
"   <p>",
"    <strong>",
"     Central hypothyroidism versus subclinical hyperthyroidism",
"    </strong>",
"    &mdash; A patient with a low-normal serum total or free T4 value and a detectable but subnormal serum TSH concentration (eg, free T4 0.9 to 1.1",
"    <span class=\"nowrap\">",
"     ng/dL,",
"    </span>",
"    TSH 0.2 to 0.5",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    could have either central hypothyroidism or subclinical hyperthyroidism.",
"   </p>",
"   <p>",
"    In this setting, serum T3 should be measured. Rarely, patients with subclinical hyperthyroidism who have low-normal free T4 values can have high-normal T3 values. The finding of a normal or high-normal serum T3 is consistent with subclinical hyperthyroidism. We then obtain a thyroid scan and uptake, looking for thyroid autonomy. If the scan shows areas of autonomy, and the 24-hour uptake is normal or high-normal, autonomously functioning thyroid nodules or multinodular goiter are the most likely cause of subclinical hyperthyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=see_link&amp;anchor=H16#H16\">",
"     \"Subclinical hyperthyroidism\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the T3 is normal or low-normal, we evaluate for coexisting pituitary hormone abnormalities as described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27846365\">",
"    <span class=\"h2\">",
"     TSH normal",
"    </span>",
"   </p>",
"   <p>",
"    <strong>",
"     Central hypothyroidism versus euthyroid hypothyroxinemia",
"    </strong>",
"    &mdash; Many conditions result in increases or decreases in serum total thyroxine (T4) and triiodothyronine (T3) concentrations, but little change in serum free T4 and T3 concentrations and no symptoms or signs of thyroid dysfunction. Thus, in patients with a normal TSH and low total T4 concentrations, the serum free T4 should be measured. The detection of a normal serum TSH concentration associated with a low serum total T4 and normal free T4 concentration should alert the clinician to search for one of the causes of euthyroid hypothyroxinemia, especially if the patient has no symptoms or signs of hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/53/856?source=see_link&amp;anchor=H11#H11\">",
"     \"Euthyroid hyperthyroxinemia and hypothyroxinemia\", section on 'Euthyroid hypothyroxinemia due to binding protein abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     Drug interaction",
"    </strong>",
"    &mdash; In patients with low serum total and free T4 concentrations (with a normal TSH concentration), central hypothyroidism is possible. However, certain drugs, especially antiseizure medications, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , may be associated with an artifactually low serum free T4 and a normal serum TSH, mimicking central hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/30\">",
"     30",
"    </a>",
"    ]. In this case, assessment of other pituitary functions and pituitary imaging may be required to definitively rule out central hypothyroidism. In addition, TRH testing, where available, can be very helpful in ruling out central hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients with phenytoin-induced reductions in serum total and free T4 would have a normal TSH response to TRH administration, whereas patients with central hypothyroidism would have an absent or delayed response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42632?source=see_link&amp;anchor=H17#H17\">",
"     \"Drug interactions with thyroid hormones\", section on 'Drugs that affect thyroid hormone metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H977108\">",
"    <span class=\"h2\">",
"     Transient central hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three clinical situations in which the laboratory finding of central hypothyroidism is transient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After treatment of hyperthyroidism with an antithyroid drug, radioiodine, or surgery, serum TSH concentrations remain low for approximately 25 days. Serum free T4 values may fall to below normal during this period [",
"      <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of Graves' hyperthyroidism\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=see_link&amp;anchor=H10#H10\">",
"       \"Laboratory assessment of thyroid function\", section on 'Monitoring treatment of hyperthyroidism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum TSH concentrations may remain low for a similar period after T4 therapy is discontinued in a patient with a nodular goiter [",
"      <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with severe nonthyroidal illness have transient central hypothyroidism. Thus, permanent central hypothyroidism should not be diagnosed in the presence of an underlying medical disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=see_link\">",
"       \"Thyroid function in nonthyroidal illness\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In these settings, clinical status and thyroid function tests (TSH, free T4) should be monitored serially (every two to three months) until thyroid tests return to normal. Additional evaluation is generally unnecessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H772203\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with biochemical evidence of central hypothyroidism require neuroradiologic studies (preferably MRI) to assess the hypothalamic-pituitary region. If MRI is unavailable, a CT scan with coronal views through the pituitary is a reasonable alternative.",
"   </p>",
"   <p>",
"    Biochemical assessment of other pituitary hormone deficiencies, particularly secondary adrenal insufficiency, should be performed. Administration of T4 to patients with unsuspected and untreated secondary adrenal insufficiency can precipitate an acute adrenal crisis. Thus, pituitary-adrenal function should be assessed, usually by an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    , before thyroxine (T4) therapy is begun in all patients with central hypothyroidism. If adrenal insufficiency is present, glucocorticoid therapy should be given concomitantly with T4. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation of other hypothalamic-pituitary hormonal function (gonadotropins, testosterone, estradiol, prolactin, insulin-like growth factor-I) to diagnose hormonal hypersecretion or hyposecretion is necessary in patients with a sellar mass on MRI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=see_link&amp;anchor=H22#H22\">",
"     \"Causes, presentation, and evaluation of sellar masses\", section on 'Evaluation of a sellar mass'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with normal findings on MRI, clinical and biochemical assessment of hypothalamic-pituitary hormonal function may be useful to differentiate central from mild primary hypothyroidism. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'TSH slightly high'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pituitary-adrenal function should be assessed, usually by an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    , before thyroxine (T4) therapy is begun in all patients with central hypothyroidism. If adrenal insufficiency is present, glucocorticoid therapy should be given concomitantly with T4. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=see_link\">",
"     \"Diagnosis of hypopituitarism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of choice for correction of central hypothyroidism is synthetic thyroxine (T4). We suggest starting with a weight-based T4 dose of 1.6",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/34\">",
"     34",
"    </a>",
"    ]. The dose should be adjusted according to the patient's symptoms and serum free T4 values, aiming to maintain the serum free T4 concentration in the upper 50 percent of the normal range. Another approach is to start with a lower dose and titrate to an endpoint of a mid-high normal free T4 value. Serum TSH cannot be used to monitor therapy, as it is suppressed to &lt;0.1",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    in nearly all patients taking doses of T4 that raise their serum free T4 concentrations to normal [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/35\">",
"     35",
"    </a>",
"    ]. In patients with pituitary tumors, central hypothyroidism may be reversible. Surgery may occasionally lead to an improvement in anterior pituitary function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=see_link&amp;anchor=H4#H4\">",
"     \"Causes of hypopituitarism\", section on 'Mass lesions'",
"    </a>",
"    .) Thyroid function (TSH, free T4) should be measured six weeks after surgery. If thyroid function has returned to normal, there is no need to initiate or restart T4 replacement.",
"   </p>",
"   <p>",
"    In a randomized crossover trial comparing thyroid hormone replacement regimens in patients with central hypothyroidism, higher dose T4 (1.6",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    was superior to lower dose (1",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    with respect to BMI, lipid profile, and symptoms. The resultant serum free T4 levels were at or slightly above the upper limit of normal. The widely accepted conclusion from this study is that the thyroxine dose should be adjusted according to the patient's symptoms and serum free T4 values, aiming to maintain the serum free T4 concentration in the upper part of the normal range.",
"   </p>",
"   <p>",
"    Despite the recommendations from this study, analysis of a UK database of 525 patients with pituitary tumors found that 39 percent of those with central hypothyroidism taking thyroxine had free T4 values less than 13",
"    <span class=\"nowrap\">",
"     pmol/L",
"    </span>",
"    (1.0",
"    <span class=\"nowrap\">",
"     ng/dL;",
"    </span>",
"    normal range 9 to 25",
"    <span class=\"nowrap\">",
"     pmol/L",
"    </span>",
"    [0.7 to 1.9",
"    <span class=\"nowrap\">",
"     ng/dL]),",
"    </span>",
"    compared with 13 percent of patients with primary hypothyroidism taking thyroxine, suggesting that many patients with central hypothyroidism are undertreated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The authors of another study suggest that patients with central hypothyroidism may need more T4 to achieve serum T4 values in the upper half of the normal range than patients with primary hypothyroidism caused by chronic autoimmune thyroiditis or radioiodine therapy. In this study of clinically euthyroid patients with serum free T4 index values in the upper half of the normal range, 36 patients with central hypothyroidism were receiving more T4 (155",
"    <span class=\"nowrap\">",
"     mcg/day,",
"    </span>",
"    1.9",
"    <span class=\"nowrap\">",
"     mcg/kg/day)",
"    </span>",
"    than 73 patients with hypothyroidism caused by chronic autoimmune thyroiditis or radioiodine therapy (118",
"    <span class=\"nowrap\">",
"     mcg/day,",
"    </span>",
"    1.6",
"    <span class=\"nowrap\">",
"     mcg/kg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/37\">",
"     37",
"    </a>",
"    ]. It is unclear from this study whether aiming for a high normal free T4 in patients with central hypothyroidism results in excessive replacement therapy. In another study, women taking estrogen replacement therapy, men initiating growth hormone therapy, and patients with childhood onset central hypothyroidism needed a higher dose of T4 to maintain the free T4 in the upper half of the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with central hypothyroidism may have low serum free T3 concentrations despite normal or upper normal free T4 values [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/21,27\">",
"     21,27",
"    </a>",
"    ]. The potential benefit of combined T4-T3 treatment in 29 patients with central hypothyroidism was evaluated in a five-week crossover trial comparing thyroid replacement regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?18/6/18536/abstract/34\">",
"     34",
"    </a>",
"    ]. Although compared with T4 alone (1.6",
"    <span class=\"nowrap\">",
"     mcg/kg),",
"    </span>",
"    patients receiving combined T3 (0.16",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    and T4 (1.44",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    had a small but significant improvement in total cholesterol (198 verus 194",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    and normalization of ankle reflex time (380 versus 364 msec); the combined regimen resulted in supraphysiologic free T3 levels, suggesting hyperthyroidism. Thus, there are insufficient data to determine whether combined T4 and T3 (in physiologic doses) is superior to T4 monotherapy for patients with central hypothyroidism. A full discussion of this topic, including data that suggest that a small fraction of the hypothyroid population with a polymorphism in the type 2 deiodinase might benefit from combination therapy, can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of hypothyroidism\", section on 'Combination T4 and T3 therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1276737\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central hypothyroidism refers to thyroid hormone deficiency due to a disorder of the pituitary, hypothalamus, or hypothalamic-pituitary portal circulation (",
"      <a class=\"graphic graphic_figure graphicRef75399 \" href=\"UTD.htm?10/24/10629\">",
"       figure 1",
"      </a>",
"      ). The prevalence of central hypothyroidism is much lower than that of primary hypothyroidism. Pituitary mass lesions, especially pituitary adenomas, are the most common cause of central hypothyroidism. Other mass lesions that can cause central hypothyroidism include cysts and abscesses, meningiomas and dysgerminomas, pituitary adenocarcinomas and metastatic tumors, and craniopharyngiomas, which may enter the sella or remain suprasellar (",
"      <a class=\"graphic graphic_table graphicRef55951 \" href=\"UTD.htm?18/8/18571\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of central hypothyroidism are similar to but sometimes milder than those of primary hypothyroidism. Common symptoms of hypothyroidism include fatigue, cold intolerance, muscle cramps, and weight gain. The majority of patients with central hypothyroidism have coexisting deficiency or excesses of other pituitary hormones, although isolated TSH deficiency may also occur. In patients with coexisting pituitary hormone abnormalities, the symptoms of hypothyroidism may be masked by other symptoms of hypopituitarism. (See",
"      <a class=\"local\" href=\"#H18020398\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In hypothyroidism caused by hypothalamic or pituitary disease, TSH secretion does not increase appropriately as T4 secretion falls. In patients with central hypothyroidism, serum free T4 is low or low-normal, but serum TSH may be low, normal, or even slightly elevated (up to about 10",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef67935 \" href=\"UTD.htm?26/20/26956\">",
"       table 3",
"      </a>",
"      ). In patients with pituitary tumors, there may be laboratory evidence of deficiency or excess of other pituitary hormones, such as hypogonadism or hyperprolactinemia. (See",
"      <a class=\"local\" href=\"#H18020102\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of central hypothyroidism is based upon clinical manifestations and thyroid function tests. We measure both serum TSH and free T4 if central hypothyroidism is suspected. We also measure free T4 if the patient has convincing symptoms of hypothyroidism despite a normal TSH result. In patients with central hypothyroidism, the serum free T4 value is low-normal or low and serum TSH may be frankly low, inappropriately normal (for the low T4), or slightly high (5 to 10",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"      due to secretion of biologically inactive TSH (",
"      <a class=\"graphic graphic_table graphicRef67935 \" href=\"UTD.htm?26/20/26956\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22447146\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients without previous",
"      <span class=\"nowrap\">",
"       hypothalamic/pituitary",
"      </span>",
"      disease, it may be difficult to distinguish mild central hypothyroidism from mild primary hypothyroidism or subclinical hyperthyroidism. Some drugs can affect thyroid hormone metabolism, mimicking the thyroid function test abnormalities seen in patients with central hypothyroidism. In addition, transient central hypothyroidism may occur in some settings. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with biochemical evidence of central hypothyroidism require neuroradiologic studies (preferably MRI) to assess the hypothalamic-pituitary region and biochemical assessment of the other pituitary hormones, particularly secondary adrenal insufficiency. Administration of thyroxine (T4) to patients with unsuspected and untreated secondary adrenal insufficiency can precipitate an acute adrenal crisis. Thus, pituitary-adrenal function should be assessed, usually by an",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"       ACTH stimulation test",
"      </a>",
"      , before T4 therapy is begun in all patients with central hypothyroidism, and glucocorticoid therapy should be given before or with T4 if adrenal insufficiency is present. (See",
"      <a class=\"local\" href=\"#H772203\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment for correction of central hypothyroidism is synthetic thyroxine (T4). We typically start with a weight-based T4 dose of 1.6",
"      <span class=\"nowrap\">",
"       mcg/kg.",
"      </span>",
"      Another approach is to start with a lower dose and titrate to a free T4 in the upper half of the normal range. The dose should be adjusted according to the patient's symptoms and serum free T4 values, aiming to maintain the serum free T4 concentration in the upper part of the normal range. Serum TSH cannot be used to monitor therapy, as it is suppressed to &lt;0.1",
"      <span class=\"nowrap\">",
"       mU/L",
"      </span>",
"      in nearly all patients taking doses of T4 that raise their serum free T4 concentrations to normal. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/1\">",
"      Persani L. Clinical review: Central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges. J Clin Endocrinol Metab 2012; 97:3068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/2\">",
"      Samuels MH, Ridgway EC. Central hypothyroidism. Endocrinol Metab Clin North Am 1992; 21:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/3\">",
"      Yamada M, Mori M. Mechanisms related to the pathophysiology and management of central hypothyroidism. Nat Clin Pract Endocrinol Metab 2008; 4:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/4\">",
"      Bates AS, Van't Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996; 81:1169.",
"     </a>",
"    </li>",
"    <li>",
"     CureSearch: Children's Oncology Group. file://www.survivorshipguidelines.org/ (Accessed on March 23, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/6\">",
"      Bhandare N, Kennedy L, Malyapa RS, et al. Primary and central hypothyroidism after radiotherapy for head-and-neck tumors. Int J Radiat Oncol Biol Phys 2007; 68:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/7\">",
"      Thodou E, Asa SL, Kontogeorgos G, et al. Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings. J Clin Endocrinol Metab 1995; 80:2302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/8\">",
"      Benvenga S, Vigo T, Ruggeri RM, et al. Severe head trauma in patients with unexplained central hypothyroidism. Am J Med 2004; 116:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/9\">",
"      Pf&auml;ffle RW, DiMattia GE, Parks JS, et al. Mutation of the POU-specific domain of Pit-1 and hypopituitarism without pituitary hypoplasia. Science 1992; 257:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/10\">",
"      Collu R, Tang J, Castagn&eacute; J, et al. A novel mechanism for isolated central hypothyroidism: inactivating mutations in the thyrotropin-releasing hormone receptor gene. J Clin Endocrinol Metab 1997; 82:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/11\">",
"      Hayashizaki Y, Hiraoka Y, Tatsumi K, et al. Deoxyribonucleic acid analyses of five families with familial inherited thyroid stimulating hormone deficiency. J Clin Endocrinol Metab 1990; 71:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/12\">",
"      Dacou-Voutetakis C, Feltquate DM, Drakopoulou M, et al. Familial hypothyroidism caused by a nonsense mutation in the thyroid-stimulating hormone beta-subunit gene. Am J Hum Genet 1990; 46:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/13\">",
"      Medeiros-Neto G, Herodotou DT, Rajan S, et al. A circulating, biologically inactive thyrotropin caused by a mutation in the beta subunit gene. J Clin Invest 1996; 97:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/14\">",
"      Bonomi M, Proverbio MC, Weber G, et al. Hyperplastic pituitary gland, high serum glycoprotein hormone alpha-subunit, and variable circulating thyrotropin (TSH) levels as hallmark of central hypothyroidism due to mutations of the TSH beta gene. J Clin Endocrinol Metab 2001; 86:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/15\">",
"      Muthukrishnan J, Harikumar KV, Verma A, Modi K. Central hypothyroidism. Indian J Pediatr 2010; 77:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/16\">",
"      Gharib H, Abboud CF. Primary idiopathic hypothalamic hypothyroidism. Report of four cases. Am J Med 1987; 83:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/17\">",
"      Yamakita N, Komaki T, Takao T, et al. Usefulness of thyrotropin (TSH)-releasing hormone test and nocturnal surge of TSH for diagnosis of isolated deficit of TSH secretion. J Clin Endocrinol Metab 2001; 86:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/18\">",
"      Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 1999; 340:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/19\">",
"      Agha A, Walker D, Perry L, et al. Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients. Clin Endocrinol (Oxf) 2007; 66:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/20\">",
"      Porretti S, Giavoli C, Ronchi C, et al. Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T(4) therapy become mandatory? J Clin Endocrinol Metab 2002; 87:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/21\">",
"      Alexopoulou O, Beguin C, De Nayer P, Maiter D. Clinical and hormonal characteristics of central hypothyroidism at diagnosis and during follow-up in adult patients. Eur J Endocrinol 2004; 150:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/22\">",
"      Beck-Peccoz P, Amr S, Menezes-Ferreira MM, et al. Decreased receptor binding of biologically inactive thyrotropin in central hypothyroidism. Effect of treatment with thyrotropin-releasing hormone. N Engl J Med 1985; 312:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/23\">",
"      Persani L, Ferretti E, Borgato S, et al. Circulating thyrotropin bioactivity in sporadic central hypothyroidism. J Clin Endocrinol Metab 2000; 85:3631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/24\">",
"      Miura Y, Perkel VS, Papenberg KA, et al. Concanavalin-A, lentil, and ricin lectin affinity binding characteristics of human thyrotropin: differences in the sialylation of thyrotropin in sera of euthyroid, primary, and central hypothyroid patients. J Clin Endocrinol Metab 1989; 69:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/25\">",
"      Samuels MH, Lillehei K, Kleinschmidt-Demasters BK, et al. Patterns of pulsatile pituitary glycoprotein secretion in central hypothyroidism and hypogonadism. J Clin Endocrinol Metab 1990; 70:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/26\">",
"      Caron PJ, Nieman LK, Rose SR, Nisula BC. Deficient nocturnal surge of thyrotropin in central hypothyroidism. J Clin Endocrinol Metab 1986; 62:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/27\">",
"      Ferretti E, Persani L, Jaffrain-Rea ML, et al. Evaluation of the adequacy of levothyroxine replacement therapy in patients with central hypothyroidism. J Clin Endocrinol Metab 1999; 84:924.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.pathology.leedsth.nhs.uk/dnn_bilm/Investigationprotocols/Pituitaryprotocols/TRHTest.aspx (Accessed on September 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/29\">",
"      Hartoft-Nielsen ML, Lange M, Rasmussen AK, et al. Thyrotropin-releasing hormone stimulation test in patients with pituitary pathology. Horm Res 2004; 61:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/30\">",
"      Surks MI, DeFesi CR. Normal serum free thyroid hormone concentrations in patients treated with phenytoin or carbamazepine. A paradox resolved. JAMA 1996; 275:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/31\">",
"      Connacher AA, Borsey DQ, Browning MC, et al. The effective evaluation of thyroid status in patients on phenytoin, carbamazepine or sodium valproate attending an epilepsy clinic. Postgrad Med J 1987; 63:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/32\">",
"      Uy HL, Reasner CA, Samuels MH. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves' disease. Am J Med 1995; 99:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/33\">",
"      Vagenakis AG, Braverman LE, Azizi F, et al. Recovery of pituitary thyrotropic function after withdrawal of prolonged thyroid-suppression therapy. N Engl J Med 1975; 293:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/34\">",
"      Slawik M, Klawitter B, Meiser E, et al. Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine. J Clin Endocrinol Metab 2007; 92:4115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/35\">",
"      Shimon I, Cohen O, Lubetsky A, Olchovsky D. Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism. Thyroid 2002; 12:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/36\">",
"      Koulouri O, Auldin MA, Agarwal R, et al. Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine. Clin Endocrinol (Oxf) 2011; 74:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/6/18536/abstract/37\">",
"      Gordon MB, Gordon MS. Variations in adequate levothyroxine replacement therapy in patients with different causes of hypothyroidism. Endocr Pract 1999; 5:233.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7849 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-7B7E1375F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_6_18536=[""].join("\n");
var outline_f18_6_18536=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1276737\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18020064\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18020398\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18020102\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18020410\">",
"      - Thyroid function tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18020236\">",
"      - TRH stimulation test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H977219\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22447146\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TSH slightly high",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TSH low",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27846365\">",
"      TSH normal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H977108\">",
"      Transient central hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H772203\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1276737\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7849\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7849|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/24/10629\" title=\"figure 1\">",
"      Regulation thyroid hormone production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7849|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/8/18571\" title=\"table 1\">",
"      Causes of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/41/42651\" title=\"table 2\">",
"      Symptoms and signs of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/20/26956\" title=\"table 3\">",
"      Assessment of thyroid function",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=related_link\">",
"      Causes of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=related_link\">",
"      Causes, presentation, and evaluation of sellar masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=related_link\">",
"      Clinical features and detection of congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=related_link\">",
"      Diagnosis of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=related_link\">",
"      Diagnosis of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42632?source=related_link\">",
"      Drug interactions with thyroid hormones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/856?source=related_link\">",
"      Euthyroid hyperthyroxinemia and hypothyroxinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39223?source=related_link\">",
"      Growth failure after childhood cancer: Role of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=related_link\">",
"      Laboratory assessment of thyroid function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=related_link\">",
"      Subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=related_link\">",
"      Subclinical hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=related_link\">",
"      Thyroid function in nonthyroidal illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=related_link\">",
"      Thyroid hormone synthesis and physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/46/15081?source=related_link\">",
"      Treatment and prognosis of congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=related_link\">",
"      Treatment of Graves' hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_6_18537="Rifampin, isoniazid, and pyrazinamide: Drug information";
var content_f18_6_18537=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rifampin, isoniazid, and pyrazinamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/20/31045?source=see_link\">",
"    see \"Rifampin, isoniazid, and pyrazinamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rifater&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Rifater&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F218324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F218313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Tuberculosis:",
"     </b>",
"     Oral: Patients weighing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &le;44 kg: 4 tablets once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     45-54 kg: 5 tablets once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &ge;55 kg: 6 tablets once daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F7727372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Tuberculosis:",
"     </b>",
"     Oral: Children &ge;15 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F218314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to dosing in individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F11347629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; contraindicated with severe or acute impairment. Monitor liver function closely; discontinue treatment if signs of hepatic damage occur.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F218300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Rifater&reg;: Rifampin 120 mg, isoniazid 50 mg, and pyrazinamide 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F218289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7727464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer dose either 1 hour before or 2 hours after a meal with a full glass of water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F218302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial phase, short-course treatment of pulmonary tuberculosis; see individual agents for additional information",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6053103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Rifater&reg; may be confused with Rifadin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F218322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     During clinical trial evaluation, the frequency of cardiorespiratory events (eg, chest pain, hemoptysis, palpitation, chest tightness, and pneumothorax) was higher with the combination product (7%) than that reported with individual agents (2%); frequency of central and peripheral nervous system events (eg, sweating, headache, insomnia, paresthesia, and anxiety) were also higher with the combination product (4%) than that reported with individual agents (3%).",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F639167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Hypersensitivity to rifampin, isoniazid, pyrazinamide, or any component of the formulation; severe hepatic damage; acute liver disease; acute gout; history of severe adverse reactions to isoniazid (eg, drug fever, chills, or arthritis); concurrent use of atazanavir, darunavir, fosamprenavir, saquinavir, saquinavir/ritonavir, or tipranavir",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F218292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Flu-like syndrome: Regimens of rifampin &gt;600 mg once or twice weekly have been associated with a high incidence of adverse reactions including a flu-like syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: May cause thrombocytopenia, leukopenia, or anemia with regimens of rifampin &gt;600 mg once or twice weekly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatitis:",
"     <b>",
"      [U.S. Boxed Warning]: Severe and sometimes fatal hepatitis may occur with isoniazid; increased transaminase concentrations usually occur within the first 3 months of treatment, although may develop even after many months of treatment.",
"     </b>",
"     The risk of developing hepatitis is age-related; daily ethanol consumption may also increase the risk. Patients must report any prodromal symptoms of hepatitis, such as fatigue, weakness, malaise, anorexia, nausea, or vomiting. Discontinue isoniazid if hepatic damage occurs; if therapy must be restarted, initiate at a lower dose once symptoms and laboratory abnormalities have resolved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperbilirubinemia: Discontinue therapy if this occurs in conjunction with clinical symptoms or any signs of significant hepatocellular damage develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Hypersensitivity reactions have occurred in patients taking &gt;600 mg of rifampin once or twice weekly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuropathies: Pyridoxine (10-50 mg/day) is recommended in individuals at risk for development of peripheral neuropathies (eg, HIV infection, nutritional deficiency, diabetes, pregnancy).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Alcoholism: Use with caution in patients with a history of alcoholism (even if ethanol consumption is discontinued during therapy).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: Pyrazinamide may inhibit uric acid excretion; acute gouty attacks have been reported. Use with caution in patients with chronic gout; contraindicated with acute gout. All patients should undergo evaluation of baseline serum uric acid levels and periodically thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Rifampin, isoniazid, and pyrazinamide are all associated with liver impairment. Use with caution in patients with hepatic impairment; dosage reduction may be necessary. Patients with existing hepatic impairment should undergo evaluation of liver function tests prior to initiating therapy and every 2-4 weeks thereafter; discontinue therapy if signs of hepatocellular damage occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Meningococcal disease: Do not use for meningococcal disease, only for short-term treatment of asymptomatic carrier states.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with porphyria; exacerbations have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tuberculosis: Appropriate use: Current guidelines for the treatment of adults with previously untreated tuberculosis recommend that a four-drug regimen consisting of rifampin, isoniazid, pyrazinamide, and ethambutol be administered in the initial phase of treatment until drug susceptibility has been confirmed. Refer to current CDC guidelines for more information (CDC, 2003).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Medications associated with hepatotoxicity: Use with caution in patients receiving concurrent medications associated with hepatotoxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Compliance: Monitor for compliance. Patients should avoid therapy interruption; rare renal hypersensitivity reactions have been reported following resumption of therapy in such patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lenses: Remove soft contact lenses during therapy since permanent staining may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ophthalmic examinations: Periodic ophthalmic examinations are recommended even when visual symptoms do not occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Red/orange discoloration: Urine, feces, saliva, sweat, tears, and CSF may be discolored to red/orange.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F218320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F218296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Isoniazid may enhance the adverse/toxic effect of Acetaminophen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Rifamycin Derivatives may decrease the serum concentration of Alfentanil.  Management: Monitor closely for decreased alfentanil effectiveness.  Increased alfentanil doses will likely be needed.  Alternatively, changing from alfentanil to a different opioid anesthetic (e.g., sufentanil) may also be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Rifamycin Derivatives may increase the metabolism of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Rifamycin Derivatives may increase the metabolism of Angiotensin II Receptor Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Candesartan; Eprosartan; Olmesartan; Telmisartan; Valsartan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Isoniazid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Rifampin may increase the metabolism of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiemetics (5HT3 Antagonists): Rifamycin Derivatives may increase the metabolism of Antiemetics (5HT3 Antagonists).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dolasetron; Granisetron; Palonosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): Rifamycin Derivatives may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Rifamycin Derivatives. Only rifabutin appears to be affected.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: Rifamycin Derivatives may increase the metabolism of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Rifampin may decrease the serum concentration of Atazanavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atovaquone: Rifamycin Derivatives may decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: Rifamycin Derivatives may increase the metabolism of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: CYP1A2 Inducers (Strong) may decrease the serum concentration of Bendamustine. Concentrations of active metabolites may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Rifamycin Derivatives may increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Isoniazid may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Rifamycin Derivatives may decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Carteolol (Ophthalmic); Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: Rifampin may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: Rifampin may decrease the serum concentration of Bosentan. Following the initial several weeks of concurrent rifampin, this effect is most likely. Rifampin may increase the serum concentration of Bosentan. This effect is most likely to be observed within the initial few weeks of concurrent therapy (and may be greatest immediately following initiation of the combination).  Management: Weekly monitoring of liver function tests during the first 4 weeks of concurrent therapy is recommended, with a return to normal recommended monitoring thereafter as appropriate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Rifamycin Derivatives may decrease the serum concentration of BusPIRone.  Management: The degree to which rifampin alters buspirone concentrations warrants the consideration of an alternative to buspirone that is not metabolized by CYP3A4.  If these agents are used together, buspirone dose adjustments may be needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Rifamycin Derivatives may increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.  Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: Rifampin may decrease the serum concentration of Canagliflozin.  Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR &gt;60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require greater glycemic control. Consider alternatives in patients with estimated GFR 45-60 mL/min/1.73 m2.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Isoniazid may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caspofungin: Rifampin may decrease the serum concentration of Caspofungin.  Management: Caspofungin prescribing information recommends using a dose of 70 mg daily in adults (or 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , up to a maximum of 70 mg, daily in pediatric patients) who are also receiving rifampin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: Rifampin may increase the metabolism of Chloramphenicol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chlorzoxazone: Isoniazid may decrease the metabolism of Chlorzoxazone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Strong) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a strong CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Rifamycin Derivatives may enhance the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: Rifampin may decrease the serum concentration of Cobicistat.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Rifamycin Derivatives may decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Rifamycin Derivatives may decrease the serum concentration of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Rifamycin Derivatives may increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May decrease the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSERINE: Isoniazid may enhance the adverse/toxic effect of CycloSERINE. Specifically, CNS toxicity may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Rifamycin Derivatives may increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Pyrazinamide may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inducers (Strong) may increase the metabolism of CYP1A2 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2A6 Substrates: CYP2A6 Inhibitors (Moderate) may decrease the metabolism of CYP2A6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inducers (Strong) may increase the metabolism of CYP2B6 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inducers (Strong) may increase the metabolism of CYP2C19 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Strong) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inducers (Strong) may increase the metabolism of CYP2C8 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inducers (Strong) may increase the metabolism of CYP2C9 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2E1 Substrates: CYP2E1 Inhibitors (Moderate) may decrease the metabolism of CYP2E1 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP2E1 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Rifamycin Derivatives may increase the metabolism of Dapsone (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: Rifampin may decrease the serum concentration of Darunavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Rifampin may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May decrease the metabolism of Rifamycin Derivatives. Rifamycin Derivatives may increase the metabolism of Delavirdine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inducers (Strong) may decrease the serum concentration of Diclofenac (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Rifamycin Derivatives may decrease the serum concentration of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May enhance the adverse/toxic effect of Isoniazid. Disulfiram may increase the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Rifampin may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: Rifampin may decrease the serum concentration of Efavirenz.  Management: Increase efavirenz adult dose to 800 mg daily in patients weighing over 50 kg (per U.S. manufacturer; CDC sets this at 60 kg, and Canadian manufacturer recommends the dose increase regardless of weight).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Rifampin may decrease the serum concentration of Elvitegravir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP2C8 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Rifampin may increase the metabolism of Erlotinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Esomeprazole: Rifampin may decrease the serum concentration of Esomeprazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethionamide: May increase the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Rifamycin Derivatives may decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Rifamycin Derivatives may decrease the serum concentration of FentaNYL.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fexofenadine: Rifampin may decrease the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Rifamycin Derivatives. This appears only affect rifabutin. Rifamycin Derivatives may increase the metabolism of Fluconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: Rifampin may decrease the serum concentration of Fosamprenavir. Specifically, concentrations of amprenavir (active metabolite) may be decreased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: Rifampin may decrease the serum concentration of Fosaprepitant. More specifically, rifampin may decrease concentrations of the active metabolite aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Isoniazid may increase the serum concentration of Fosphenytoin.  Management: Consider alternatives. If concomitant therapy cannot be avoided, monitor for increased phenytoin concentrations/effects with isoniazid initiation/dose increase, or decreased concentrations/effects with isoniazid discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Rifamycin Derivatives may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Rifamycin Derivatives may increase the metabolism of Gefitinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Rifamycin Derivatives may decrease the serum concentration of HMG-CoA Reductase Inhibitors.  Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pitavastatin; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Rifamycin Derivatives may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with the rifamycin derivatives when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Rifampin may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Rifamycin Derivatives may enhance the hepatotoxic effect of Isoniazid. Even so, this is a frequently employed combination regimen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Isoniazid may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Isoniazid may decrease the serum concentration of Ketoconazole (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Rifampin may increase the metabolism of LamoTRIgine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Rifampin may increase serum concentrations of the active metabolite(s) of Leflunomide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: Rifampin may enhance the adverse/toxic effect of Lopinavir. Specifically, the risk of hepatocellular toxicity may be increased. Rifampin may decrease the serum concentration of Lopinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Rifamycin Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Rifamycin Derivatives may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Rifampin may decrease the serum concentration of Mirabegron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Morphine (Systemic): Rifamycin Derivatives may decrease the serum concentration of Morphine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Rifamycin Derivatives may decrease the serum concentration of Mycophenolate. Specifically, rifamycin derivatives may decrease the concentration of the active metabolite mycophenolic acid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Rifampin may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: Rifampin may decrease the serum concentration of Nevirapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omeprazole: Rifampin may decrease the serum concentration of Omeprazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OxyCODONE: Rifampin may decrease the serum concentration of OxyCODONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Isoniazid may increase the serum concentration of Phenytoin.  Management: Consider alternatives. If concomitant therapy cannot be avoided, monitor for increased phenytoin concentrations/effects with isoniazid initiation/dose increase, or decreased concentrations/effects with isoniazid discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Rifamycin Derivatives may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inducers (Strong) may decrease the serum concentration of Pirfenidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pitavastatin: Rifamycin Derivatives may increase the serum concentration of Pitavastatin.  Management: Limit pitavastatin dose to a maximum of 2 mg/day with concurrent rifampin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP1A2 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: Rifampin may diminish the antiplatelet effect of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Rifamycin Derivatives may decrease the serum concentration of Propafenone.  Management: Monitor propafenone serum concentrations closely with rifamycin initiation/dose adjustments/discontinuation. Propafenone serum concentrations/therapeutic effects  may decrease with rifamycins. Propafenone dose adjustments may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyrazinamide: May enhance the hepatotoxic effect of Rifampin. Severe (even fatal) liver injury has been reported in patients receiving these 2 drugs as a 2-month treatment regimen for latent TB infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Rifamycin Derivatives may decrease the serum concentration of QuiNIDine.  Management: Consider alternatives to combination treatment with quinidine and rifampin due to large potential decreases in quinidine concentrations. Monitor for decreased quinidine concentrations/effects with initiation/dose increase of any rifamycin derivative.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Rifampin may decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Rifampin may decrease the serum concentration of Raltegravir.  Management: Increase raltegravir dose to 800 mg twice daily (adult dose) when used concomitantly with rifampin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ramelteon: Rifamycin Derivatives may increase the metabolism of Ramelteon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: Rifampin may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Rifamycin Derivatives may increase the metabolism of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: Pyrazinamide may enhance the hepatotoxic effect of Rifampin. Severe (even fatal) liver injury has been reported in patients receiving these 2 drugs as a 2-month treatment regimen for latent TB infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May enhance the hepatotoxic effect of Isoniazid. Even so, this is a frequently employed combination regimen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Rifamycin Derivatives may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: Rifampin may decrease the serum concentration of Ritonavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: Rifampin may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining rifampin with roflumilast.  The Canadian product monograph makes no such recommendation but notes that rifampin may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Rifampin may enhance the adverse/toxic effect of Saquinavir. Specifically, the risk of hepatocellular toxicity may be increased. Rifampin may decrease the serum concentration of Saquinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Rifampin may increase the metabolism of Sirolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Rifampin may increase the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Rifamycin Derivatives may increase the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: Rifamycin Derivatives may increase the metabolism of Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Rifampin may decrease the serum concentration of Telaprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Rifamycin Derivatives may decrease the serum concentration of Temsirolimus. Rifamycins will likely cause an even greater decrease in the concentration of the active metabolite sirolimus.  Management: Temsirolimus prescribing information recommends against coadministration with strong CYP3A4 inducers such as rifampin; however, if concurrent therapy is necessary, an increase in temsirolimus adult dose to 50 mg/week should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terbinafine (Systemic): Rifampin may decrease the serum concentration of Terbinafine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Isoniazid may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Rifampin may decrease the serum concentration of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Rifampin may decrease the serum concentration of Tipranavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: CYP2C8 Inducers (Strong) may decrease the serum concentration of Treprostinil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Rifampin may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Rifamycin Derivatives may increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Rifamycin Derivatives. Rifamycin Derivatives may decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zaleplon: Rifamycin Derivatives may increase the metabolism of Zaleplon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Rifamycin Derivatives may decrease the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: Rifamycin Derivatives may decrease the serum concentration of Zolpidem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F639169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F218297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F218306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F218316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16330629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rifampin, isoniazid, and pyrazinamide enter breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F218307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose should be taken either 1 hour before or 2 hours after a meal with a full glass of water. Avoid tyramine-containing foods; some examples include aged or matured cheese, air-dried or cured meats (including sausages and salamis), fava or broad bean pods, tap/draft beers, Marmite concentrate, sauerkraut, soy sauce and other soybean condiments. Avoid histamine-containing foods (eg, tuna or other tropical fish).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F218305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Rifater Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-120-300 mg (60): $250.57",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7727373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline and periodic liver function tests, serum uric acid, serum bilirubin, serum creatinine, CBC; patients at higher risk for hepatitis (eg, existing hepatic impairment, older patients, ethanol consumption, alcoholism) should undergo evaluation of liver function tests every 2-4 weeks. Monitor for prodromal signs of hepatitis; monitor sputum cultures monthly (until 2 consecutive negative cultures reported); monitor chest x-ray 2-3 months into treatment and at completion.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F218308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Rifater (AT, BF, BJ, CH, CI, CL, DE, ES, ET, FR, GB, GH, GM, GN, GR, HK, IE, IN, IT, KE, LR, MA, ML, MR, MU, MW, NE, NG, PH, PK, PT, SC, SD, SL, SN, TH, TN, TW, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Rimcure (DK, NO, SE);",
"     </li>",
"     <li>",
"      Rimcure 3-FDC (MY);",
"     </li>",
"     <li>",
"      Yu Yu Rifater (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7727339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin inhibits bacterial mRNA synthesis by binding to the beta subunit of DNA-dependent RNA polymerase, blocking transcription",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid inhibits mycolic acid synthesis resulting in disruption of the bacterial cell wall",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyrazinamide is converted to pyrazinoic acid in susceptible strains of",
"     <i>",
"      Mycobacterium",
"     </i>",
"     which lowers the pH of the environment; exact mechanism of action has not been elucidated",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F218304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Treatment of Tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2003, 52(RR-11):1-77.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10078 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-211.167.112.17-380DEE3FB3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_6_18537=[""].join("\n");
var outline_f18_6_18537=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709401\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218310\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218311\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218324\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218313\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7727372\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218314\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11347629\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218300\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218289\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7727464\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218302\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6053103\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218322\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F639167\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218292\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218320\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218296\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F639169\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218297\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218306\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218316\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16330629\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218307\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218305\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7727373\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218308\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7727339\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218304\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10078\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10078|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/20/31045?source=related_link\">",
"      Rifampin, isoniazid, and pyrazinamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_6_18538="Uterine septum at hysteroscopy";
var content_f18_6_18538=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79425%7EOBGYN%2F53717%7EOBGYN%2F62456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79425%7EOBGYN%2F53717%7EOBGYN%2F62456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Uterine septum separating uterine cavity into two horns",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Wire resection of uterine septum via hysteroscope",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 393px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Septum resected and uterine cavity now unified",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 417px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_6_18538=[""].join("\n");
var outline_f18_6_18538=null;
var title_f18_6_18539="Primary graft dysfn severity";
var content_f18_6_18539=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for grading of primary graft dysfunction (PGD) severity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Grade",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pa0",
"        <sub>",
"         2",
"        </sub>",
"        /Fi0",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Radiographic infiltrates consistent with pulmonary edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        &gt;300",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &gt;300",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        200-300",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        &lt;200",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Christie, JD, Carby, M, Bag, R, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction Part II: Definition. A Consensus Statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2005; 24:1454. Copyright &copy; 2006 The International Society for Heart and Lung Transplantation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_6_18539=[""].join("\n");
var outline_f18_6_18539=null;
var title_f18_6_18540="Causes central cyanosis newborn";
var content_f18_6_18540=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of central cyanosis in the neonate",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Right-to-left shunt",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intracardiac level: cyanotic disease, anomalous systemic venous connection to left atrium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Great vessel level: persistent pulmonary hypertension of the newborn",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intrapulmonary level: pulmonary arteriovenous malformation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Ventilation/perfusion mismatch",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Airway disease: pneumonia, aspiration, cystic adenomatoid malformation, diaphragmatic hernia, pulmonary hypoplasia, lobar emphysema, atelectasis, pulmonary hemorrhage, hyaline membrane disease, transient tachypnea of the newborn",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extrinsic compression of lungs: pneumothorax, pleural effusion, chylothorax, hemothorax, thoracic dystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Alveolar hypoventilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central nervous system depression: asphyxia, maternal sedation, intraventricular hemorrhage, seizure, meningitis, encephalitis, apnea of prematurity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuromuscular disease: Werdnig-Hoffman disease, neonatal myasthenia gravis, phrenic nerve injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Airway obstruction: choanal atresia, laryngotracheomalacia, macroglossia, Pierre Robin syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hemoglobinopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methemoglobinemia: congenital or secondary to toxic exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other hemoglobinopathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diffusion impairment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary edema: left-sided obstructive cardiac disease, cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital lymphangiectasia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <br>",
"       <ol>",
"        <li>",
"         Lees MH. J Pediatr 1970; 77:484.",
"        </li>",
"        <li>",
"         Marino BS, Bird GL, Wernovsky G. Clin Perinatol 2001; 28:91.",
"        </li>",
"        <li>",
"         Baum VC, McDaniel NL. Cyanosis. In: Ambulatory Pediatric Care, 3rd ed, Dershewitz RA (Ed), Lippincott-Raven, Philadelphia 1999. p.921.",
"        </li>",
"       </ol>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_6_18540=[""].join("\n");
var outline_f18_6_18540=null;
var title_f18_6_18541="Pretreatment evaluation MF";
var content_f18_6_18541=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F75528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F75528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended evaluation/initial staging of the patient with mycosis fungoides/S&eacute;zary syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Evaluation and staging",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Complete physical examination, including:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Determination of type(s) of skin lesions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Estimate percentage of BSA involved by patches, plaques, and tumor lesions and note any ulceration or folliculocentricity of lesions. The patient's palm (including all fingers) is approximately 1 percent of BSA*.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Identification of any palpable lymph node, especially those &ge;1.5 cm in largest diameter or firm, irregular, clustered, or fixed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Identification of any organomegaly",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Skin biopsy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Essential: At least two skin biopsies should be obtained of different anatomic areas and morphology for H&amp;E evaluation. If only one biopsy can be obtained, then the lesion that has the most scaling and induration should be chosen.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       If needed: Immunophenotyping to include at least the following markers: CD2, CD3, CD4, CD5, CD7, and CD8, beta-F1 (to confirm alpha-beta TCR), and a B-cell marker, such as CD20; CD30 may also be indicated in cases where lymphomatoid papulosis, anaplastic lymphoma, or large-cell transformation is considered.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       If needed: Evaluation for clonality of TCR gene rearrangement",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Blood tests",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       CBC with manual differential (assess for Sezary cells), comprehensive chemistries, LDH",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Analysis for abnormal lymphocytes by either Sezary cell count with determination of the absolute number of Sezary cells and/or flow cytometry (including CD4",
"       <sup>",
"        +",
"       </sup>",
"       / CD7",
"       <sup>",
"        -",
"       </sup>",
"       or CD4",
"       <sup>",
"        +",
"       </sup>",
"       / CD26",
"       <sup>",
"        -",
"       </sup>",
"       )",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       If needed: TCR gene rearrangement and relatedness to any clone in skin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Radiologic tests",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       In patients with T",
"       <sub>",
"        1",
"       </sub>",
"       N",
"       <sub>",
"        0",
"       </sub>",
"       B",
"       <sub>",
"        0",
"       </sub>",
"       stage disease who are otherwise healthy and without complaints directed to a specific organ system; and in selected patients with T",
"       <sub>",
"        2",
"       </sub>",
"       N",
"       <sub>",
"        0",
"       </sub>",
"       B",
"       <sub>",
"        0",
"       </sub>",
"       disease with limited skin involvement, radiologic studies may be limited to a chest x-ray.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       In all other patients, contrast-enhanced CT scan of chest, abdomen, and pelvis (neck included if clinically indicated) or whole body integrated PET-CT is recommended to further evaluate any potential lymphadenopathy, visceral involvement, or abnormal laboratory tests; in patients unable to safely undergo CT scans, MRI may be substituted.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Lymph node biopsy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Excisional biopsy is indicated in those patients with a node that is at least 1.5 cm (confirmed by imaging) in diameter; and/or is firm, irregular, clustered, or fixed; and/or significantly PET avid.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Site of biopsy: Preference is given to the largest lymph node draining an involved area of the skin or if FDG-PET scan data are available, the node with highest standardized uptake value.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Analysis: Pathologic assessment by light microscopy, flow cytometry, and TCR gene rearrangement",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BSA: Body surface area; TCR: T-cell receptor; CBC: complete blood count; CT: Computed tomography; MRI: Magnetic resonance imaging; FDG-PET:",
"     <sup>",
"      18",
"     </sup>",
"     F-fluoro-2-deoxyglucose positron emission tomography.",
"     <br>",
"      *A more specific BSA calculation can be calculated using the \"mSWAT\" system: mSWAT = (percent BSA of patches) (1) + (percent BSA of plaques) (2) + (percent BSA of tumor) (4).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     This table was created using research originally published in Blood. Prince HM, Whittaker S, Hoppe RT. How I treat my mycosis fungoides and S&eacute;zary syndrome. Blood 2009; 114:4337. Copyright &copy; American Society of Hematology. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and S&eacute;zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110:1713. Copyright &copy; American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_6_18541=[""].join("\n");
var outline_f18_6_18541=null;
var title_f18_6_18542="Staphylococcal adenitis";
var content_f18_6_18542=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Staphylococcus aureus adenitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 291px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Acute unilateral cervical adenitis caused by",
"    <em>",
"     S. aureus",
"    </em>",
"    . Submandibular nodes are affected in more than 50 percent of cases. The lymph node is usually 3 to 6 cm in diameter, tender, warm, erythematous, nondiscrete, and poorly mobile.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_6_18542=[""].join("\n");
var outline_f18_6_18542=null;
var title_f18_6_18543="Dysostosis metacarpal";
var content_f18_6_18543=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dysostosis metacarpal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 260px; height: 393px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dysostosis multiplex manifested as proximal pointing of metacarpals.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ed Wraith, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_6_18543=[""].join("\n");
var outline_f18_6_18543=null;
